General References

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

K
Kaan HY, Weiss J, Menger D et al. Structure-activity relationship and multidrug resistance study of new S-trityl-l-Cysteine derivatives as inhibitors of Eg5. J Med Chem 2011; 54:1576-86.

Kabashima K, Murata T, Tanaka H et al. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immun 2003; 4:694-701.

Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003; 9:744-9.

Kabat GC, Etgen AM, Rohan TE. Do steroid hormones play a role in the etiology of glioma? Cancer Epidemiol Biomarkers Prev 2010; 19:2421-7.

Kabesch M. Pharmacogenetics of beta(2)-agonists in children. J Allergy Clin Immunol 2009; 124:1195-6.

Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 2008; 4:137-49.

Kacirova I, Grundmann M, Brozmanova H. Serum levels of lamotrigine during delivery in mothers and their infants. Epilepsy Res 2010; 91:161-5.

Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16:297-306.

Kaddar N, Vigneault P, Pilote S, Patoine D, Simard C, Drolet B. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther 2011. doi:10. 1177/1074248410395020.

Kadlubar FF, Berkowitz GS, Delongchamp RR et al. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:327-31.

Kadoglou NP, Kostomitsopoulos N, Kapelouzou A et al. Effects of exercise training on the severity and composition of atherosclerotic plaque in apoE-deficient mice. J Vasc Res 2011; 48:347-56.

Kadokura T, den Adel M, Krauwinkel WJ, Takeshige T, Nishida A. The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects. Eur J Clin Pharmacol 2008; 64:605-9.

Kadono K, Akabane T, Tabata K, Gato K, Terashita S, Teramura T. Quantitative prediction of intestinal metabolism in humans from simplified Fg model and empirical scaling factor. Drug Metab Dispos 2010; 38:1230-7.

Kadotani H, Kadotani T, Young T et al. Association between apolipoprotein E epsilon-4 and sleep-disordered breathing in adults. JAMA 2001; 285:2888-90.

Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother 2009; 53:609-14.

Kafert-Kasting S, Alexandrova K, Barthold M et al. Enzyme induction in cryopreserved human hepatocyte cultures. Toxicology 2006; 220:117-25.

Kagan L, Dreifinger T, Mager DE, Hoffman A. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos 2010; 38:1560-6.

Kagawa N. Efficient expression of human aromatase (CYP19) in E. coli. Methods Mol Biol 2011; 705:109-22.

Kagerer SM, Eichholz C, Jöhren O. Orexins/hypocretins increase the promoter activity of selective steroidogenic enzymes. Peptides 2011; 32:839-43.

Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990; 265:17209-14.

Kaila T, Iisalo E. Selectivity of acebutolol, atenolol, and metoprolol in healthy volunteers estimated by the extent the drugs occupy beta 2-receptors in the circulating plasma. J Clin Pharmacol 1993; 33:959-66.

Kaipiainen-Seppänen O, Savolainen E, Elfving P, Kononoff A. Adverse muscle effects of a podofyllotoxin-containing cytotoxic drug product with simvastatin. Duodecim 2009; 125:788-91.

Kaiqiang Ji, Minakawa M, Fukui K, Suzuki Y, Fukuda I. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Ther Adv Cardiovasc Dis 2009; 3:103-11.

Kaisary A, Smith P, Jaczq E et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47:5488-93.

Kaiser R, Tremblay PB, Sezer O, Possinger K, Roots I, Brockmöller J. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 2004; 14:271-8.

Kaiser S, Park YK, Franklin JL et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007; 8:131.

Kajbaf M, Palmieri E, Longhi R, Fontana S. Identifying a Higher Throughput Assay for Metabolism Dependent Inhibition (MDI). Drug Metab Lett 2010; 4:104-113.

Kajihara S, Hisatomi A, Mizuta T et al. A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem Biophys Res Commun 1998; 253:454-7.

Kajinami K, Akao H, Polisecki E, Schaefer EJ. Pharmacogenomics of statin responsiveness. Am J Cardiol 2005; 96:65-70.

Kajinami K, Brousseau ME, Lamon-Fava S, Ordovas JM, Schaefer EJ. Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis 2005; 178:331-8.

Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93:104-7.

Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. A promoter polymorphism in cholesterol 7 alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 2005; 180:407-15.

Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential forgenotype-based individualization of coronary heart disease management. Atherosclerosis 2004; 177:219-34.

Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003; 21:199-215.

Kajita J, Inano K, Fuse E, Kuwabara T, Kobayashi H. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos 2002; 30:1504-11.

Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000; 28:1121-7.

Kajkowski EM, Lo CF, Ning X et al. Beta-amyloid peptide-induced apoptosis regulated by a novel protein containing a G protein activation module. J Biol Chem 2001; 276:18748-56.

Kajosaari LI, Jaakkola T, Neuvonen PJ, Backman JT. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 2006; 62:217-23.

Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 2005; 97:249-56.

Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther 2006; 79:231-42.

Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78:388-99.

Kakan X, Chen P, Zhang J. Clock gene mPer2 functions in diurnal variation of acetaminophen induced hepatotoxicity in mice. Exp Toxicol Pathol 2011; 63:581-5.

Kakar SM, Paine MF, Stewart PW, Watkins PB. 6’7’-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 2004; 75:569-79.

Kakihara S, Yoshimura R, Shinkai K et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005; 20:71-8.

Kaklamani VG, Hou N, Bian Y et al. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 2003; 21:3236-43.

Kakoki M, McGarrah RW, Kim HS, Smithies O. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Nat Acad Sci USA 2007; 104:7576-81.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 2010; 15:817-29.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011; 50:25-39.

Kaladchibachi SA, Doble B, Anthopoulos N, Woodgett JR, Manoukian AS. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J Circadian Rhythms 2007; 5:3.

Kalalinia F, Elahian F, Behravan J. Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J Cancer Res Clin Oncol 2011; 137:321-30.

Kalchman M, Koide H, McCutcheon K et al. HIP1, a human homologue of S. cerevisiae Slap2, interacts with membrane-associated huntingtin in the brain. Nat Genet 1997; 16:44-53.

Kale VM, Miranda SR, Wilbanks MS, Meyer SA. Comparative cytotoxicity of alachlor, acetochlor, and metolachlor herbicides in isolated rat and cryopreserved human hepatocytes. J Biochem Mol Toxicol 2008; 22:41-50.

Kalev I, Oselin K, Pärlist P et al. CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications 2003; 17:387-91.

Kalfa N, Méduri G, Philibert P et al. Unusual virilization in girls with juvenile granulosa cell tumors of the ovary is related to intratumoral aromatase deficiency. Horm Res Paediatr 2010; 74:83-91.

Kalgutkar AS, Frederick KS, Chupka J et al. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a “chemical knock-out equivalent” to assess the impact of efflux transporters on oral drug absorption in the rat. J Pharm Sci 2009; 98:4914-27.

Kalgutkar AS, Hatch HL, Kosea F et al. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Biopharm Drug Dispos 2006; 27:371-86.

Kalgutkar AS, Nguyen HT, Vaz AD et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003; 31:1240-50.

Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos 2003; 31:243-9.

Kalgutkar AS, Tugnait M, Zhu T et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos 2011; 39:1609-19.

Kalgutkar AS, Zhou S, Fahmi OA, Taylor TJ. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6. Drug Metab Dispos 2003; 31:596-605.

Kalikaki A, Kanaki M, Vassalou H et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10:118-23.

Kaliszczak M, Antonow D, Patel KI et al. Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J 2010; 12:617-27.

Kalita J, Misra UK, Bindu IS, Kumar B, Mittal B. Angiotensin-converting enzyme(rs4646994) and α ADDUCIN (rs4961) gene polymorphisms’ study in primary spontaneous intracerebral hemorrhage. Neurol India 2011; 59:41-6.

Kalita J, Somarajan BI, Kumar B, Mittal B, Misra UK. A study of ACE and ADD1 polymorphism in ischemic and hemorrhagic stroke. Clin Chim Acta 2011; 412:642-6.

Kalmes M, Hennen J, Clemens J, Blömeke B. Impact of aryl hydrocarbon receptor (AhR) knockdown on cell cycle progression in human HaCaT keratinocytes. Biol Chem 2011; 392:643-51.

Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49:369-79.

Kalsi G, Sherrington R, Mankoo BS et al. Linkage study of the D5 dopamine receptor gene (DRD5) in multiplex Icelandic and English schizophrenia pedigrees. Am J Psychiatry 1996; 153:107-9.

Kalthoff S, Ehmer U, Freiberg N, Manns MP, Strassburg CP. Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010; 139:1699-710.

Kalthoff S, Ehmer U, Freiberg N, Manns MP, Strassburg CP. Interaction between oxidative stress sensor Nrf2 and xenobiotic-activated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDP-glucuronosyltransferase 1A10. J Biol Chem 2010; 285:5993-6002.

Kallianpur AR, Hulgan T, Canter JA et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006; 20:1503-13.

Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H, Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J Clin Endocrinol Metab 2003; 88:3278-83.

Kallio JP, Hopkins-Donaldson S, Baker AH, Kähäri VM. TIMP-3 promotes apoptosis in nonadherent small cell lung carcinoma cells lacking functional death receptor pathway. Int J Cancer 2011; 128:991-6.

Kamada T, Chow T, Hiroi T et al. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet 2002; 17:199-206.

Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LSB. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2001; 414:643-8.

Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010; 61:63-75.

Kamali-Sarvestani E, Nikseresht A, Aflaki E, Sarvari J, Gharesi-Fard B. TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis. Acta Neurol Scand 2007; 115:161-6.

Kamataki T, Fujita K, Nakayama K, Yamazaki Y, Miyamoto M, Ariyoshi N. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metab Rev 2002; 34:667-76.

Kamatani Y, Wattanapokayakit S, Ochi H et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41:591-5.

Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol 2005; 56:145-53.

Kambur O, Männistö PT, Viljakka K et al. Stress-induced analgesia and morphine responses are changed in catechol-O-methyltransferase-deficient male mice. Basic Clin Pharmacol Toxicol 2008; 103:367-73.

Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011; 39:98-105.

Kamdem LK, Hamilton L, Cheng C et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2008; 18:507-14.

Kamdem LK, Liu Y, Stearns V et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010; 70:854-69.

Kamdem LK, Meineke I, Gödtel-Armbrust U, Brockmöller J, Wojnowski L. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res Toxicol 2006; 19:577-86.

Kamdem LK, Meineke I, Koch I, Zanger UM, Brockmöller J, Wojnowski L. Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol 2004; 370:71-7.

Kamdem LK, Streit F, Zanger UM et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51:1374-81.

Kameoka K, Isotani H, Tanaka K et al. Novel mitochondrial DNA mutation in tRNA(Lys) (8296A→G) associated with diabetes. Biochem Biophys Res Commun 1998; 245:523-7.

Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 7:513-22.

Kamijo A, Kimura K, Sugaya T et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004; 143:23-30.

Kamimura H, Oishi S, Matsushima H et al. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998; 28:909-22.

Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73:67-74.

Kamischke A, Baumgardt A, Horst J, Nieschlag E. Clinical and diagnostic features of patients with suspected Klinefelter syndrome. J Androl 2003; 24:41-8.

Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010; 86:52-8.

Kamiyama E, Yoshigae Y, Kasuya A, Takei M, Kurihara A, Ikeda T. Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes. Drug Metab Pharmacokinet 2007; 22:267-75.

Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007; 22:287-98.

Kammerer B, Scheible H, Albrecht W, Gleiter CH, Laufer S. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor. Drug Metab Dispos 2007; 35:875-83.

Kammerer S, Braun A, Arnold N, Roscher AA. The human bradykinin B(2) receptor gene: full length cDNA, genomic organization and identification of the regulatory region. Biochem Biophys Res Commun 1995; 211:226-33.

Kampman O, Antilla S, Illi A et al. Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. J Hum Genet 2004; 49:355-9.

Kamrath C, Maser-Gluth C, Haag C, Schulze E. Diagnosis of glucocorticoid-remediable aldosteronism in hypertensive children. Horm Res Paediatr 2011; 76:93-8.

Kan R, Wang B, Zhang C et al. Association of the HTR6 polymorphism C267T with late-onset Alzheimer’s disease in Chinese. Neurosci Lett 2004; 372:27-9.

Kanai M, Yoshioka A, Tanaka S et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 2010; 34:189-93.

Kanamaluru D, Xiao Z, Fang S et al. Arginine methylation by PRMT5 at a naturally occurring mutation site is critical for liver metabolic regulation by small heterodimer partner. Mol Cell Biol 2011; 31:1540-50.

Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000; 17:419-26.

Kanamori M, Takahashi H, Echizen H. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther 2002; 40:485-92.

Kanamori Y, Fujita K, Nakayama K, Kawai H, Kamataki T. Large-scale production of genetically engineered CYP3A4 in E. coli: application of a jarfermenter. Drug Metab Pharmacokinet 2003; 18:42-7.

Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94:339-41.

Kanayama N, Kanari C, Masuda Y, Ohmori S, Ooie T. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica 2007; 37:139-54.

Kanazawa H, Okada A, Higaki M, Yokota H, Mashige F, Nakahara K. Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. J Pharm Biomed Anal 2003; 30:1817-24.

Kanazawa H, Tateishi Y, Yoshikawa J. Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms. Clin Physiol Funct Imaging 2004; 24:224-8.

Kanazu T, Okamura N, Yamaguchi Y, Baba T, Koike M. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica 2005; 35:305-17.

Kanda D, Takagi H, Kawahara Y et al. Novel large-scale deletion (whole exon 7) in the ABCC2 gene in a patient with the Dubin-Johnson syndrome. Drug Metab Pharmacokinet 2009; 24:464-8.

Kane GC, Behfar A, Dyer RB et al. KCNJ11 gene knockout of the Kir6. 2 KATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet 2006; 15:2285-97.

Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008; 36:137-45.

Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 2008; 36:1444-52.

Kanebratt KP, Diczfalusy U, Bäckström T et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 2008; 84:589-94.

Kaneda M, Schuetz M, Lin BS et al. ABC transporters coordinately expressed during lignification of Arabidopsis stems include a set of ABCBs associated with auxin transport. J Exp Bot 2011; 62:2063-77.

Kaneko A, Kato M, Sekiguchi N, Mitsui T, Takeda K, Aso Y. In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells. Xenobiotica 2009; 39:803-10.

Kaneko Y, Nakayama T, Saito K et al. Relationship between the thromboxane A2 receptor gene and susceptibility to cerebral infarction. Hypertens Res 2006; 9:665-71.

Kanekura T, Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 2010; 57:149-54.

Kanellakis P, Agrotis A, Kyaw TS et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31:313-9.

Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 2002; 23:77-81.

Kang BH, Siegelin MD, Plescia J et al. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 2010; 16:4779-88.

Kang DE, Pietrzik CU, Baum Let al. Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106:1159-66.

Kang HA, Cho HY, Lee YB. The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Arch Pharm Res 2007; 30:96-101.

Kang HJ, Hong YB, Kim HJ et al. Detoxification: a novel function of BRCA1 in tumor suppression? Toxicol Sci 2011; 122:26-37.

Kang HJ, Oh Y, Chun SM et al. TotalPlex gene amplification using bulging primers for pharmacogenetic analysis of acute lymphoblastic leukemia. Mol Cell Probes 2008; 22:193-200.

Kang J, Cheng B, Jiang L. PPARγ signal transduction pathway in the foam cell formation induced by visfatin. Sheng Li Xue Bao 2010; 62:427-32.

Kang JH, Chung WG, Lee KH et al. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. Pharmacogenetics 2000; 10:67-78.

Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging 2010. doi:10. 1016/j. neurobiolaging. 2010. 10. 007.

Kang JH, Lee da H, Seo H et al. Regulation of functional phenotypes of cord blood derived eosinophils by gamma-secretase inhibitor. Am J Respir Cell Mol Biol 2007; 37:571-7.

Kang JW, Wilkerson HW, Farin FM et al. Mammalian cytochrome CYP2E1 triggered differential gene regulation in response to trichloroethylene (TCE) in a transgenic poplar. Funct Integr Genomics 2010; 10:417-24.

Kang KW, Choi JS. Enhanced bioavailability of paclitaxel by bamboo concentrate administration. Arch Pharm Res 2005; 28:469-75.

Kang MH, Singaraja R, Hayden MR. Adenosine-triphosphate-binding cassette transporter-1 trafficking and function. Trends Cardiovasc Med 2010; 20:41-9.

Kang MR, Lee K, Kang JS et al. KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein. Oncol Rep 2010; 23:801-9.

Kang P, Dalvie D, Smith E, Zhou S, Deese A. Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos 2007; 35:1081-8.

Kang P, Dalvie D, Smith E, Zhou S, Deese A, Nieman JA. Bioactivation of flutamide metabolites by human liver microsomes. Drug Metab Dispos 2008; 36:1425-37.

Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos 2008; 36:490-9.

Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med 2007; 37:315-29.

Kang RH, Jung SM, Kim KA et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol 2009; 29:272-7.

Kang YS, Park SY, Yim CH et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009; 85:312-8.

Kanintronkul Y, Worayuthakarn R, Thasana N et al. Overcoming multidrug resistance in human lung cancer with novel Benzo[a]quinolizin-4-ones. Anticancer Res 2011; 31:921-7.

Kaniwa N, Kurose K, Jinno H et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos 2005; 33:458-65.

Kanki H, Yang P, Xie HG, Kim RB, George AL Jr, Roden DM. Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol 2002; 13:252-6.

Kannan P, Brimacombe KR, Zoghbi SS et al. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos 2010; 38:917-22.

Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113:1489-94.

Kanno Y, Inoue Y, Inouye Y. 5-aminoimidazole-4-carboxamide-1-beta-ribofuranoside (AICAR) prevents nuclear translocation of constitutive androstane receptor by AMP-activated protein kinase (AMPK) independent manner. J Toxicol Sci 2010; 35:571-6.

Kaňová N, Bičíková M. Hyperandrogenic states in pregnancy. Physiol Res 2011; 60:243-52.

Kantarci OH, Hebrink DD, Schaefer-Klein J et al. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression. Arch Neurol 2008; 65:349-57.

Kantarci OH, Morales Y, Ziemer PA et al. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 2005; 169:137-43.

Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540-6.

Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63:397-402.

Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64:58-65.

Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64:177-82.

Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 1999; 54:851-5.

Kanwar SS, Yu Y, Nautiyal J et al. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011; 28:827-38.

Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M. Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet Med 2002; 19:212-5.

Kapelyukh Y, Paine MJ, Maréchal JD, Sutcliffe MJ, Wolf CR, Roberts GC. Multiple substrate binding by cytochrome P450 3A4: estimation of the number of bound substrate molecules. Drug Metab Dispos 2008; 36:2136-44.

Kapitanović S, Cacev T, Antica M et al. Effect of indomethacin on E-cadherin and beta-catenin expression in HT-29 colon cancer cells. Exp Mol Pathol 2006; 80:91-6.

Kaplan HL, Busto UE, Baylon GJ et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997; 281:103-8.

Kapoor G, Sinha R, Naithani R, Chandgothia M. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Leuk Res 2010; 34:1023-6.

Kapoor N, Pant AB, Dhawan A et al. Differences in sensitivity of cultured rat brain neuronal and glial cytochrome P450 2E1 to ethanol. Life Sci 2006; 79:1514-22.

Kappelhoff BS, Huitema AD, Mairuhu AT, Schellens JH, Beijnen JH. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anticancer Drugs 2005; 16:627-30.

Kappers WA, Edwards RJ, Murray S, Boobis AR. Diazinon is activated by CYP2C19 in human liver. Toxicol Appl Pharmacol 2001; 177:68-76.

Kappers WA, Groene EM, Kleij LA et al. Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P4502C10. Xenobiotica 1996; 26:1231-9.

Kappert K, Tsuprykov O, Kaufmann J et al. Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. Hypertension 2009; 54:738-43.

Kapucuoglu N, Coban T, Raunio H et al. Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett 2003; 202:17-23.

Karaali ZE, Sozen S, Yurdum M et al. Effect of genetic variants of chemokine receptors on the development of myocardial infarction in Turkish population. Mol Biol Rep 2010; 37:3615-9.

Karahalil B, Coskun E, Emerce E. ADRA2A polymorphism and smoking in a Turkish population. Toxicol Ind Health 2008; 24:171-6.

Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996; 24:1081-7.

Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007; 39:851-6.

Karanam BV, Hop CE, Liu DQ et al. In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases. Drug Metab Dispos 2004; 32:1015-22.

Karanam BV, Welch CJ, Reddy VG, Chilenski J, Biba M, Vincent S. Species differential stereoselective oxidation of a methylsulfide metabolite of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor dual agonist. Drug Metab Dispos 2004; 32:1061-8.

Karashima S, Takeda Y, Cheng Y et al. Clinical characteristics of primary hyperaldosteronism due to adrenal microadenoma. Steroids 2011; 76:1363-6.

Karassa FB, Bijl M, Davies KA et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003; 48:1930-8.

Karim A, Noveck R, McMahon FG et al. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol 1997; 37:267-78.

Kariv I, Fereshteh MP, Oldenburg KR. Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J Biomol Screen 2001; 6:91-9.

Karl M, Lamberts SW, Detera-Wadleigh SD et al. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab 1993; 76:683-9.

Karl M, Lamberts SW, Koper JW et al. Cushing’s disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assoc Am Physicians 1996; 108:296-307.

Karlsson L, Hiemke C, Carlsson B et al. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology 2011; 215:367-77.

Karlsson L, Schmitt U, Josefsson M et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 2010; 20:632-40.

Karmaus W, Osuch JR, Landgraf J, Taffe B, Mikucki D, Haan P. Prenatal and concurrent exposure to halogenated organic compounds and gene expression of CYP17A1, CYP19A1, and oestrogen receptor alpha and beta genes. Occup Environ Med 2011; 68:430-7.

Karol MD, Locke CS, Cavanaugh JH. Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment. J Clin Pharmacol 2000; 40:301-8.

Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 2010; 88:223-30.

Karonen T, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. Eur J Clin Pharmacol 2011; 67:151-5.

Karp JE, Smith BD, Levis MJ et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007; 13:4467-73.

Karper JC, de Vries MR, van den Brand BT et al. Toll-like receptor 4 is involved in human and mouse vein graft remodeling, and local gene silencing reduces vein graft disease in hypercholesterolemic APOE*3Leiden mice. Arterioscler Thromb Vasc Biol 2011; 31:1033-40.

Karpyak VM, Biernacka JM, Weg MW et al. Interaction of SLC6A4 and DRD2 polymorphisms is associated with a history of delirium tremens. Addict Biol 2010; 15:23-34.

Karten B, Peake KB, Vance JE. Mechanisms and consequences of impaired lipid trafficking in Niemann-Pick type C1-deficient mammalian cells. Biochim Biophys Acta 2009; 179:659-70.

Karttunen V, Myllynen P, Prochazka G, Pelkonen O, Segerbäck D, Vähäkangas K. Placental transfer and DNA binding of benzo(a)pyrene in human placental perfusion. Toxicol Lett 2010; 197:75-81.

Karuna R, Holleboom AG, Motazacker MM et al. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis 2011; 214:448-55.

Karvonen MK, Koulu M, Pesonen U et al. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children. J Clin Endocrinol Metab 2000; 85:1455-60.

Karvonen MK, Pesonen U, Koulu M et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4:1434-7.

Karyekar CS, Eddington ND, Dowling TC. Effect of St. John’s Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells. J Postgrad Med 2002; 48:97-100.

Kasahara M, Suzuki H, Komiya I. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms. Drug Metab Dispos 2000; 28:409-17.

Kasai N, Fukushima K, Ueki Y et al. Genomic structures of SCN2A and SCN3A – candidate genes for deafness at the DFNA16 locus. Gene 2001; 264:113-22.

Kasai N, Ikushiro S, Hirosue S et al. Enzymatic properties of cytochrome P450 catalyzing 3’-hydroxylation of naringenin from the white-rot fungus Phanerochaete chrysosporium. Biochem Biophys Res Commun 2009; 387:103-8.

Kasajima A, Sers C, Sasano H et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum Pathol 2010; 41:1758-69.

Kashuba AD, Nafziger AN, Kearns GL et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998; 64:257-68.

Kashyap MP, Singh AK, Kumar V et al. Monocrotophos induced apoptosis in PC12 cells: role of xenobiotic metabolizing cytochrome P450s. PLoS One 2011. doi:10. 1371/journal. pone. 0017757.

Kashyap VS, Santamarina-Fojo S, Brown DR et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995; 96:1612-20.

Kasimsetty SG, Bialonska D, Reddy MK, Thornton C, Willett KL, Ferreira D. Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. J Agric Food Chem 2009; 57:10636-44.

Kasinathan RS, Morgan WM, Greenberg RM. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol 2010; 173:25-31.

Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 17:251-64.

Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8. 3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 2011; 82:681-91.

Kaspera R, Naraharisetti SB, Tamraz B et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenet Genomics 2010; 20:619-29.

Kassahun K, Skordos K, McIntosh I et al. Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem Res Toxicol 2005; 18:1427-37.

Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 2011. doi:10. 1016/j. thromres. 2011. 07. 022.

Kassiri Z, Defamie V, Hariri M et al. Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem 2009; 284:29893-904.

Kassiri Z, Zhong J, Guo D et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2009; 2:446-55.

Kastbom A, Bratt J, Ernestam S et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:448-52.

Kastelic M, Koprivsek J, Plesnicar BK et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:387-92.

Kastelova A, Yanev S. Propranolol as an inhibitor of some cytochrome P450-dependent monooxygenase activities in native and induced rat liver microsomes. Methods Find Exp Clin Pharmacol 2002; 24:189-94.

Kasuya F, Tatsuki T, Ohta M, Kawai Y, Igarashi K. Purification, characterization, and mass spectrometric sequencing of a medium chain acyl-CoA synthetase from mouse liver mitochondria and comparisons with the homologues of rat and bovine. Protein Expr Purif 2006; 47:405-14.

Katayama K, Shibata K, Mitsuhashi J, Noguchi K, Sugimoto Y. Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling. Anticancer Res 2009; 29:1059-65.

Katayama R, Koike S, Sato S, Sugimoto Y, Tsuruo T, Fujita N. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci 2009; 100:2060-8.

Kater B, Hunold A, Schmalz HG et al. Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative. J Cancer Res Clin Oncol 2011; 137:639-49.

Katewa SD, Katyare SS. Antimalarials inhibit human erythrocyte membrane acetylcholinesterase. Drug Chem Toxicol 2005; 28:467-82.

Kathiresan S, Melander O, Anevski D et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008; 358:1240-9.

Kathiresan S, Willer CJ, Peloso GM et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.

Kathirvel E, Chen P, Morgan K, French SW, Morgan TR. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 2010; 25:1136-43.

Kathman SJ, Williams DH, Hodge JP, Dar M. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemother Pharmacol 2009; 63:469-76.

Kato D, Kawanishi C, Kishida I et al. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. Psychiatry Clin Neurosci 2005; 59:504-7.

Kato D, Kawanishi C, Kishida I et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 2007; 63:991-6.

Kato I, Cichon M, Yee CL, Land S, Korczak JF. African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Cancer Epidemiol 2009; 33:24-30.

Kato M. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab Pharmacokinet 2008; 23:87-94.

Kato M, Chiba K, Hisaka A et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 2003; 18:365-72.

Kato M, Fukuda T, Serretti A et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:398-404.

Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006; 53:186-95.

Kato M, Fukuda T, Wakeno M et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2009; 150:115-23.

Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15:473-500.

Kato R, Moriguchi J, Irie T et al. Effects of lipopolysaccharide on P-glycoprotein expression and activity in the liver and kidneys. Eur J Pharmacol 2010; 636:155-8.

Kato S, Naito Z, Matsuda N et al. Localization of cytochrome P4502E1 enzyme in normal and cancerous gastric mucosa and association with its genetic polymorphism in unoperated and remnant stomach. J Nihon Med Sch 2011; 78:224-34.

Kato S, Yoshizazawa T, Kitanaka S, Murayama A, Takeyama K. Molecular genetics of vitamin D- dependent hereditary rickets. Horm Res 2002; 57:73-8.

Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007; 61:3-19.

Kato T, Kure T, Chang J-H et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2001; 508:187-90.

Kato Y, Fujii T, Mizoguchi N et al. Potential interaction between ritonavir and carbamazepine. Pharmacotherapy 2000; 20:851-4.

Kato Y, Ikushiro S, Emi Y et al. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Metab Dispos 2008; 36:51-5.

Katoh M, Katoh M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol 2010; 36:415-20.

Katoh M, Matsui T, Nakajima M et al. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 2004; 32:1402-10.

Katoh M, Matsui T, Nakajima M et al. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 2005; 33:754-63.

Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000; 55:843-52.

Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 2000; 17:1189-97.

Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001; 12:505-13.

Katoh M, Sawada T, Soeno Y et al. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 2007; 96:428-37.

Katoh M, Watanabe M, Tabata T et al. In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica 2005; 35:863-75.

Katoh M, Yokoi T. Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 2007; 39:145-57.

Katoh T, Saitoh H, Ohno N et al. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn Heart J 2003; 44:225-34.

Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 2001; 57:709-15.

Katsumata A, Kimura M, Saigo H et al. Changes in Esculeoside A content in different regions of the tomato fruit during maturation and heat processing. J Agric Food Chem 2011; 59:4104-10.

Katsuya T, Koike G, Yee TW et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995; 345:1600-3.

Katsuya T, Ogihara T. Trends in hypertension research. Nippon Rinsho 2006; 64 Suppl 5:5-11.

Katz A, Udata C, Ott E et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 2009; 49:643-9.

Katz DA, Grimm DR, Cassar SC et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004; 75:516-28.

Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; 141 Suppl 56:26-32.

Katzov H, Bennet AM, Hoglund K et al. Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta(1-42) and plasma apolipoprotein levels. J Hum Genet 2006; 51:171-9.

Katzov H, Bennet AM, Kehoe P et al. A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. Hum Molec Genet 2004; 13:2647-57.

Katzov H, Chalmers K, Palmgren J et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat 2004; 23:358-67.

Kaufman BD, Auerbach S, Reddy S et al. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Hum Genet 2007; 122:515-23.

Kaufmann P, Haschke M, Török M et al. Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin. Ther Drug Monit 2006; 28:766-74.

Kauhanen J, Karvonen MK, Pesonen U et al. Neuropeptide Y polymorphism and alcohol consumption in middle-aged men. Am J Med Genet 2000; 93:117-21.

Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 1997; 62:510-7.

Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53:445-9.

Kaune KM, Neumann C, Hallermann C, Haller F, Schön MP, Middel P. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. Exp Dermatol 2011; 20:331-5.

Kaur K, Mandal AK, Chakrabarti S. Primary congenital glaucoma and the involvement of CYP1B1. Middle East Afr J Ophthalmol 2011; 18:7-16.

Kaur R, Nagpal JK, Das BR. Polymorphism in IGF-2 as a surrogate marker for predisposition towards tobacco chewing-mediated oral cancer. Tumour Biol 2005; 26:147-52.

Kaur-Knudsen D, Nordestgaard BG, Tybjaerg-Hansen A, Bojesen SE. CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50,000 individuals. Pharmacogenet Genomics 2009; 19:685-94.

Kaushal N, Robson MJ, Vinnakota H et al. Synthesis and pharmacological evaluation of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J 2011; 13:336-46.

Kavallaris M, Madafiglio J, Norris MD, Haber M. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells. Biochem Biophys Res Commun 1993; 190:79-85.

Kavanagh K, Davis MA, Zhang L et al. Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys. Arterioscler Thromb Vasc Biol 2009; 29:1471-7.

Kaviarasan S, Ramamurthy N, Gunasekaran P, Varalakshmi E, Anuradha CV. Induction of alcohol-metabolizing enzymes and heat shock protein expression by ethanol and modulation by fenugreek seed polyphenols in Chang liver cells. Toxicol Mech Methods 2009; 19:116-22.

Kawaguchi A, Ohmori M, Tsuruoka S et al. Drug interaction between St John’s Wort and quazepam. Br J Clin Pharmacol 2004; 58:403-10.

Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene. Cancer Sci 2010; 101:1493-500.

Kawahara I, Kato Y, Suzuki H et al. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos 2000; 28:1238-43.

Kawahara M, Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer’s disease: The integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis 2011. doi:10. 4061/2011/276393.

Kawahara M, Ohtsuka I, Yokoyama S, Kato-Negishi M, Sadakane Y. Membrane incorporation, channel formation, and disruption of calcium homeostasis by Alzheimer’s β-Amyloid protein. Int J Alzheimers Dis 2011. doi:10. 4061/2011/304583.

Kawai M, Chen J, Cheung CY, Chang TK. Transcript profiling of cytochrome P450 genes in HL-60 human leukemic cells: upregulation of CYP1B1 by all-trans-retinoic acid. Mol Cell Biochem 2003; 248:57-65.

Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56:72-6.

Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263:131-3.

Kawajiri K, Watanabe J, Gotoh O, Tagashira Y, Sogawa K, Fujii-Kuriyama Y. Structure and drug inducibility of the human cytochrome P-450c gene. Eur J Biochem 1986; 159:219-25.

Kawamata J, Tanaka S, Shimohama S, Ueda K, Kimura J. Apolipoprotein E polymorphism in Japanese patients with Alzheimer’s disease or vascular dementia. J Neurol Neurosurg Psychiat 1994; 57:1414-6.

Kawami M, Yumoto R, Nagai J et al. Effect of Thai plant extracts on P-glycoprotein function and viability in paclitaxel-resistant HepG2 cells. Drug Metab Pharmacokinet 2010; 25:155-62.

Kawamura K, Konno F, Yui J et al. Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med 2010; 24:403-12.

Kawamura K, Yamasaki T, Konno F et al. Synthesis and in vivo evaluation of 18F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters. Bioorg Med Chem 2011; 19:861-70.

Kawana K, Ikuta T, Kobayashi Y, Gotoh O, Takeda K, Kawajiri K. Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol 2003; 63:524-31.

Kawanishi C. Genetic predisposition to neuroleptic malignant syndrome: implications for antipsychotic therapy. Am J Pharmacogenomics 2003; 3:89-95.

Kawanishi C, Furuno T, Onishi H et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr Genet 2000; 10:145-7.

Kawanishi C, Shimoda Y, Fujimaki J et al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 1998; 160:102-4.

Kawarazaki H, Ando K, Fujita M et al. Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am J Physiol Renal Physiol 2011; 300:1402-9.

Kawasaki T, Hirashima R, Maruta T et al. Cloning and characterization of a gene cluster for hatomarubigin biosynthesis in Streptomyces sp. strain 2238-SVT4. Appl Environ Microbiol 2010; 76:4201-6.

Kawase A, Fujii A, Negoro M et al. Differences in cytochrome P450 and nuclear receptor mRNA levels in liver and small intestines between SD and DA rats. Drug Metab Pharmacokinet 2008; 23:196-206.

Kawase A, Matsumoto Y, Hadano M, Ishii Y, Iwaki M. Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice. J Pharm Pharm Sci 2009; 12:150-63.

Kawase T, Matsuo K, Hiraki A et al. Interaction of the effects of alcohol drinking and polymorphisms in alcohol-metabolizing enzymes on the risk of female breast cancer in Japan. J Epidemiol 2009; 19:244-50.

Kawashima T, Noguchi E, Arinami T et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 1998; 35:502-4.

Kawashiri MA, Kobayashi J, Nohara A et al. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study. Clin Chim Acta 2011; 412:1068-75.

Kawashiro T, Yamashita K, Zhao XJ et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998; 286:1294-300.

Kay AD, Petzold A, Kerr M, Keir G, Thompson E, Nicoll JA. Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury. J Neurotrauma 2003; 20:943-52.

Kayaaltı Z, Söylemezoğlu T. Distribution of ADH1B, ALDH2, CYP2E1 *6, and CYP2E1 *7B genotypes in Turkish population. Alcohol 2010; 44:415-23.

Kayasuga R, Sugimoto Y, Watanabe T, Kamei C. Histamine H1 receptors are involved in mouse nasal allergic responses: a demonstration with H1 receptor-deficient mice. Int Immunopharmacol 2002; 2:745-50.

Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003; 13:379-82.

Kazantsev A, Walker H, Slepko N et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet 2002; 30:367-76.

Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000; 287:1837-40.

Kazierad DJ, Martin DE, Blum RA et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62:417-25.

Kazmierczak A, Strosznajder JB, Adamczyk A. alpha-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells. Neurochem Int 2008; 53:263-9.

Kazui M, Nishiya Y, Ishizuka T et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38:92-9.

Kealey C, Brown KS, Woodside JV et al. A common insertion/deletion polymorphism of the thymidylate synthase (TYMS) gene is a determinant of red blood cell folate and homocysteine concentrations. Hum Genet 2005; 116:347-53.

Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3:247-68.

Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother 1993; 27:74-9.

Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 Allele on the pharmacokinetics of omeprazole and pantoprazole in children: Evidence for a differential effect. Drug Metab Dispos 2010; 38:894-7.

Kearns GL, Robinson PK, Wilson JT et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003; 74:312-25.

Keating AF, Rajapaksa KS, Sipes IG, Hoyer PB. Effect of CYP2E1 gene deletion in mice on expression of microsomal epoxide hydrolase in response to VCD exposure. Toxicol Sci 2008; 105:351-9.

Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69:223-40.

Keating KE, Quane KA, Manning BM et al. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum Mol Genet 1994; 3:1855-8.

Keavney B, McKenzie C, Parish S et al. Large-scale test of hypothesized associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet 2000; 355:434-42.

Kebir O, Tabbane K, Sengupta S, Joober R. Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. J Psychiatry Neurosci 2009; 34:88-101.

Keck ME, Kern N, Erhardt A et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147:1196-204.

Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem 2003; 85:115-22.

Kedmi M, Maayan S, Cohen SB, Hauzi M, Rund D. MDR1 and CYP3A4 polymorphisms are associated with HIV seropositivity in Israeli patients but do not influence the course of HIV disease. AIDS Patient Care STDS 2007; 21:653-8.

Keene C, Rodrigues C, Eich T et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitroproprionic acid model of Huntington’s disease. Exp Neurol 2001; 171:351-60.

Keene C, Rodrigues C, Eich T, Chhabra M, Steer C, Low W. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington. Proc Nat Acad Sci USA 2002; 99:10671-6.

Kegel K, Meloni A, Yi Y et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 2002; 277:7466-76.

Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 1999; 36:108-11.

Kehoe PG, Russ C, McIlroy S et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 1999; 21:71-2.

Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6:373-8.

Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20:3122-9.

Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011; 71:443-54.

Kekomaki R, Dawson B, McFarland J, Kunicki TJ. Localization of human platelet autoantigens to the cysteine-rich region of glycoprotein IIIa. J Clin Invest 1991; 88:847-54.

Kelberman D, Islam L, Jacques TS et al. CYP1B1-related anterior segment developmental anomalies novel mutations for infantile glaucoma and Von Hippel’s ulcer revisited. Ophthalmology 2011; 118:1865-73.

Kelemen K, Guitart J, Kuzel TM, Goolsby CL, Peterson LC. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. Am J Clin Pathol 2008; 129:146-56.

Kelicen Ugur P, Lule S, Cincioglu M, Pekiner C, Gursoy-Ozdemir Y. Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBPβ in reperfusion injury-induced ischemic rat hippocampus. Eur J Pharmacol 2011; 654:217-25.

Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 2010; 84:825-89.

Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000; 9:2903-11.

Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem 2007; 103:2256-67.

Keller L, Xu W, Wang HX, Winblad B, Fratiglioni L, Graff C. The obesity related gene, FTO, interacts with APOE, and is associated with Alzheimer’s disease risk: a prospective cohort study. J Alzheimers Dis 2011; 23:461-9.

Kelly CM, Buzdar AU. Anastrozole. Expert Opin Drug Saf 2010; 9:995-1003.

Kelly DV, Béïque LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002; 36:827-30.

Kelly PJ, Rosand J, Kistler JP et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59:529-36.

Kelly RJ, Draper D, Chen CC et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011; 17:569-80.

Kelly RP, Close SL, Farid NA et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol 2011. doi:10. 1111/j. 1365-2125. 2011. 04049. x.

Kelly TL, Neaga OR, Schwahn BC, Rozen R, Trasler JM. Infertility in 5,10-methylenetetrahydrofolate reductase (MTHFR)-deficient male mice is partially alleviated by lifetime dietary betaine supplementation. Biol Reprod 2005; 72:667-77.

Kemal C, Casida JE. Coenzyme A esters of 2-aryloxyphenoxypropionate herbicides and 2-arylpropionate antiinflammatory drugs are potent and stereoselective inhibitors of rat liver acetyl-CoA carboxylase. Life Sci 1992; 50:533-40.

Kemp Z, Jones A. A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. Adv Ther 2011; 28:603-14.

Kendler KS, Kalsi G, Holmans PA et al. Genomewide association analysis of symptoms of alcohol dependence in the molecular genetics of Schizophrenia (MGS2) Control Sample. Alcohol Clin Exp Res 2011; 35:963-75.

Kenmotsu M, Matsuzaka K, Kokubu E, Azuma T, Inoue T. Analysis of side population cells derived from dental pulp tissue. Int Endod J 2010; 43:1132-42.

Kennedy L, Shelbourne P. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington’s disease? Hum Molec Genet 2000; 9:2539-44.

Kennedy MJ, Abdel-Rahman SM, Kashuba AD, Leeder JS. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol 2004; 44:708-14.

Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther 2008; 84:674-8.

Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement. Clin Ther 2008; 30:1687-99.

Kennedy SH. Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs 2009; 23 Suppl 2:41-7.

Kennedy SH, McCann SM, Masellis M et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002; 63:181-6.

Kennelly S, Abdullah L, Kenny RA et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients-an open-label trial. Int J Geriatr Psychiatry 2011. doi:10. 1002/gps. 2735.

Kenny JR, Chen L, McGinnity DF et al. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica 2008; 38:1500-17.

Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999; 48:716-27.

Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001; 29:1644-51.

Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003; 37:1055-62.

Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 2011:299-323.

Keramatipour M, McConnell RS, Kirkpatrick P, Tebbs S, Furlong RA, Rubinsztein DC. The ACE I allele is associated with increased risk for ruptured intracranial aneurysms. J Med Genet 2000; 37:498-500.

Kerb R, Brinkmann U, Chatskaia N et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002; 12:591-5.

Kerboeuf D, Guégnard F. Anthelmintics are substrates and activators of nematode P-glycoprotein. Antimicrob Agents Chemother 2011; 55:2224-32.

Kerbusch T, Huitema AD, Ouwerkerk J et al. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. Br J Clin Pharmacol 2000; 49:555-61.

Kerbusch T, Jansen RL, Mathôt RA et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin Pharmacol Ther 2001; 70:132-41.

Kerbusch T, Wählby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003; 56:639-52.

Kereszturi E, Tarnok Z, Bognar E et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet 2008; 147:1431-5.

Kerkela R, Kockeritz L, Macaulay K et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 2008; 118:3609-18.

Kerr B, Garcia-Rudaz C, Dorfman M, Paredes A, Ojeda SR. NTRK1 and NTRK2 receptors facilitate follicle assembly and early follicular development in the mouse ovary. Reproduction 2009; 138:131-40.

Kerr BM, Thummel KE, Wurden CJ et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-79.

Kerr ID, Haider AJ, Gelissen IC. The ABCG family of membrane-associated transporters: you don’t have to be big to be mighty. Br J Pharmacol 2010. doi:10. 1111/j. 1476-5381. 2010. 01177. x.

Kersting A, Kroker K, Horstmann J et al. Association of MAO-A variant with complicated grief in major depression. Neuropsychobiology 2007; 56:191-6.

Kertesz A. Pick Complex: an integrative approach to frontotemporal dementia: primary progressive aphasia, corticobasal degeneration, and progressive supranuclear palsy. Neurologist 2003; 9:311-7.

Kerzic PJ, Liu WS, Pan MT et al. Analysis of hydroquinone and catechol in peripheral blood of benzene-exposed workers. Chem Biol Interact 2010; 184:182-8.

Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010; 66:689-96.

Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 2004; 160:825-41.

Keskitalo J, Kurkinen K, Neuvonen P, Niemi M. ABCB1 Haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84:457–61.

Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68:207-13.

Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c. 421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009; 10:1617-24.

Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009; 86:197-203.

Kessling AM, Horsthemke B, Humphries SE. A study of DNA polymorphisms around the human apolipoprotein AI gene in hyperlipidaemic and normal individuals. Clin Genet 1985; 28:296-306.

Kester MHA, Kaptein E, Roest TJ et al. Characterization of human iodothyronine sulfotransferases. J Clin Enodcr Metab 1999; 84:1357-64.

Keul P, Lucke S, von Wnuck Lipinski K et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011; 108:314-23.

Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med 2009; 15:14-22.

Khalaf M, Mittre H, Levallet J et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells. Reprod Biomed Online 2010; 21:56-65.

Khalaila JM, Elami A, Caraco Y. Interaction between beta2 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo. Pharmacogenet Genomics 2007; 17:803-11.

Khalil WF, Saitoh T, Shimoda M, Kokue E. In vitro cytochrome P450-mediated hepatic activities for five substrates in specific pathogen free chickens. J Vet Pharmacol Ther 2001; 24:343-8.

Khalilzadeh O, Anvari M, Momen-Heravi F et al. Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves’ disease. Clin Exp Med 2010; 10:123-8.

Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001; 51:591-600.

Khan AA, Chow EC, Porte RJ, Pang KS, Groothuis GM. The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices. Toxicol In Vitro 2011; 25:80-90.

Khan AA, Chow EC, van Loenen-Weemaes AM, Porte RJ, Pang KS, Groothuis GM. Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. Eur J Pharm Sci 2009; 37:115-25.

Khan AA, Priya S, Saha B. IL-2 regulates SEB induced toxic shock syndrome in BALB/c mice. PLoS One 2009. doi:10. 1371/journal. pone. 0008473.

Khan AJ, Husain Q, Choudhuri G, Parmar D. Association of polymorphism in alcohol dehydrogenase and interaction with other genetic risk factors with alcoholic liver cirrhosis. Drug Alcohol Depend 2010; 109:190-7.

Khan AJ, Sharma A, Choudhuri G, Parmar D. Induction of blood lymphocyte cytochrome P450 2E1 in early stage alcoholic liver cirrhosis. Alcohol 2011; 45:81-7.

Khan AO. Genetics of primary glaucoma. Curr Opin Ophthalmol 2011; 22:347-55.

Khan AO, Al-Abdi L, Mohamed JY, Aldahmesh MA, Alkuraya FS. Familial juvenile glaucoma with underlying homozygous p. G61E CYP1B1 mutations. J AAPOS 2011; 15:198-9.

Khan AO, Aldahmesh MA, Alkuraya FS. Genetic and genomic analysis of classic aniridia in Saudi Arabia. Mol Vis 2011; 17:708-14.

Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 2005; 11:289-301.

Khan KK, Halpert JR. Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes. Arch Biochem Biophys 2000; 373:335-45.

Khan KK, Halpert JR. 7-Benzyloxyquinoline oxidation by P450eryF A245T: finding of a new fluorescent substrate probe. Chem Res Toxicol 2002; 15:806-14.

Khan KK, He YQ, Correia MA, Halpert JR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos 2002; 30:985-90.

Khan KK, He YQ, Domanski TL, Halpert JR. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 2002; 61:495-506.

Khan KK, Liu H, Halpert JR. Homotropic versus heterotopic cooperativity of cytochrome P450eryF: a substrate oxidation and spectral titration study. Drug Metab Dispos 2003; 31:356-9.

Khan MI, Micheal S, Akhtar F et al. The association of glutathione S-transferase GSTT1 and GSTM1 gene polymorphism with pseudoexfoliative glaucoma in a Pakistani population. Mol Vis 2010; 16:2146-52.

Khan QA, Pilch DS. Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J Mol Biol 2007; 365:561-9.

Khan S, Elshaer A, Rahman AS, Hanson P, Perrie Y, Mohammed AR. Genomic evaluation during permeability of indomethacin and its solid dispersion. J Drug Target 2011; 19:615-23.

Khan SA, Lee K, Minhas KM et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Nat Acad Sci USA 2004; 101:15944-8.

Khan SI, Zhao J, Khan IA, Walker LA, Dasmahapatra AK. Potential utility of natural products as regulators of breast cancer-associated aromatase promoters. Reprod Biol Endocrinol 2011; 9:91.

Khan ZA, Jonas SK, Feldmann KA et al. P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. J Cancer Res Clin Oncol 2001; 127:675-80.

Khanal T, Choi JH, Hwang YP, Chung YC, Jeong HG. Protective effects of saponins from the root of Platycodon grandiflorum against fatty liver in chronic ethanol feeding via the activation of AMP-dependent protein kinase. Food Chem Toxicol 2009; 47:2749-54.

Khandwala HM. Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin. South Med J 2006; 99:1385-7.

Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther 2008; 84:506-12.

Kharasch ED, Hankins DC, Fenstamaker K, Cox K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur J Clin Pharmacol 2000; 55:853-9.

Kharasch ED, Hankins DC, Jubert C, Thummel KE, Taraday JK. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Drug Metab Dispos 1999; 27:717-23.

Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004; 76:250-69.

Kharasch ED, Jubert C, Senn T, Bowdle TA, Thummel KE. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. J Clin Pharmacol 1999; 39:664-9.

Kharasch ED, Mautz D, Senn T, Lentz G, Cox K. Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 1999; 39:275-80.

Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009; 101:158-68.

Khedri A, Nejat-Shokouhi A, Salek R et al. Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep 2011; 38:2939-43.

Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 2011; 36:1-16.

Khojasteh-Bakht SC, Koenigs LL, Peter RM, Trager WF, Nelson SD. (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab Dispos 1998; 26:701-4.

Khojasteh-Bakht SC, Rossulek MI, Fouda HG, Prakash C. Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543. Xenobiotica 2003; 33:1201-10.

Khokhar JY, Miksys SL, Tyndale RF. Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. Brain Res 2010; 1348:1-9.

Khoo SM, Porter JH, Edwards GA, Charman WN. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J Pharm Sci 1998; 87:1538-41.

Khorram NM, Magee TR, Wang C, Desai M, Ross M, Khorram O. Maternal undernutrition programs offspring adrenal expression of steroidogenic enzymes. Reprod Sci 2011; 18:931-40.

Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010; 10:54-61.

Khurana R, Coleman C, Ionescu-Zanetti C et al. Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol 2005; 151:229-38.

Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106:97-132.

Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006; 94:261-71.

Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 2007; 6:33.

Kiani JG, Saeed M, Parvez SH, Frossard PM. Association of G-protein beta-3 subunit gene (GNB3) T825 allele with Type II diabetes. Neuro Endocrinol Lett 2005; 26:87-8.

Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11:803-8.

Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9:71-80.

Kido T, Sakakibara H, Ohura T et al. Evaluation of chlorinated benz[a]anthracene on hepatic toxicity in rats and mutagenic activity in Salmonella typhimurium. Environ Toxicol 2011. doi:10. 1002/tox. 20693.

Kiel S, Brüss M, Bönisch H, Göthert M. Pharmacological properties of the naturally occurring Phe-124-Cys variant of the human 5-HT1B receptor: changes in ligand binding, G-protein coupling and second messenger formation. Pharmacogenetics 2000; 10:655-66.

Kieling C, Genro JP, Hutz MH, Rohde LA. A current update on ADHD pharmacogenomics. Pharmacogenomics 2010; 11:407-19.

Kienlen-Campard P, Feyt C, Huysseune S et al. Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity. J Neurosci Res 2006; 84:1311-22.

Kiezebrink K, Mann ET, Bujac SR, Stubbins MJ, Campbell DA, Blundell JE. Evidence of complex involvement of serotonergic genes with restrictive and binge purge subtypes of anorexia nervosa. World J Biol Psychiatry 2010; 11:824-33.

Kijac AZ, Li Y, Sligar SG, Rienstra CM. Magic-angle spinning solid-state NMR spectroscopy of nanodisc-embedded human CYP3A4. Biochemistry 2007; 46:13696-703.

Kiki-Mvouaka S, Ménez C, Borin C et al. Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos 2010; 38:573-80.

Kikuchi H. Regulation of cytochrome P-450 (CYP) genes by nuclear receptors. Nippon Eiseigaku Zasshi 2002; 56:622-8.

Kikuchi R, McCown M, Olson P et al. Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver. Drug Metab Dispos 2010; 38:1954-61.

Kikumoto Y, Sugiyama H, Inoue T et al. Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice. Biochim Biophys Acta 2010; 1802:240-6.

Kikuta Y, Kusunose E, Kusunose M. Prostaglandin and leukotriene omega-hydroxylases. Prostaglandins Other Lipid Mediat 2002; 68-9:345-62.

Kikuta Y, Miyauchi Y, Kusunose E, Kusunose M. Expression and molecular cloning of human liver leukotriene B4 omega-hydroxylase (CYP4F2) gene. DNA Cell Biol 1999; 18:723-30.

Kile KB, Tian N, Durand DM. Scn2a sodium channel mutation results in hyperexcitability in the hippocampus in vitro. Epilepsia 2008; 49:488-99.

Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J 2007; 100:400-2.

Kilic E, Spudich A, Kilic U et al. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain 2008; 131:2679-89.

Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, Sellers EM. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos 2001; 29:460-5.

Kilicarslan T, Sellers EM. Lack of interaction of buprenorphine with flunitrazepam metabolism. Am J Psychiatry 2000; 157:1164-6.

Kilpeläinen TO, Lakka TA, Laaksonen DE et al. Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome: The Finnish Diabetes Prevention Study. Metabolism 2008; 57:428-36.

Killer N, Hock M, Gehlhaus M et al. Modulation of androgen and estrogen receptor expression by antiepileptic drugs and steroids in hippocampus of patients with temporal lobe epilepsy. Epilepsia 2009; 50:1875-90.

Kim BN, Kim JW, Hong SB, Cho SC, Shin MS, Yoo HJ. Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behav Brain Funct 2010; 6:57.

Kim BS, Park SM, Uhm TG et al. Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity. Pharmacogenet Genomics 2010; 20:748-58.

Kim BW, Daniels GH, Harrison BJ et al. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Metab 2003; 88:594-8.

Kim CS, Choi SJ, Park CY, Li C, Choi JS. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 2010; 30:79-85.

Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004; 101:4175-9.

Kim DH, Dai F, Belfer I et al. Polymorphic variation of the guanosine triphosphate cyclohydrolase 1 gene predicts outcome in patients undergoing surgical treatment for lumbar degenerative disc disease. Spine (Phila Pa 1976) 2010; 35:1909-14.

Kim DH, Kong JH, Byeun JY et al. The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2010; 16:5339-50.

Kim DH, Lee NY, Lee MH, Sohn SK, Do YR, Park JY. Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol 2008; 1:71-9.

Kim DH, Park JY, Sohn SK et al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 2006; 118:2195-201.

Kim DH, Sriharsha L, Xu W et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15:4750-8.

Kim DH, Vanella L, Inoue K et al. Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγ. Stem Cells Dev 2010; 19:1863-73.

Kim DK, Liu KH, Jeong JH et al. In vitro metabolism of magnolin and characterization of cytochrome P450 enzymes responsible for its metabolism in human liver microsomes. Xenobiotica 2011; 41:358-71.

Kim DN, Cho KH, Oh WS et al. EaMEAD: Activation energy prediction of cytochrome P450 mediated metabolism with effective atomic descriptors. J Chem Inf Model 2009; 49:1643-54.

Kim DW, Lee SK, Chu K et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res 2009; 84:86-90.

Kim DY, Kim MJ, Kim HB et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim Biophys Acta 2011; 1812:796-805.

Kim E, Kwon JS, Shin YW et al. Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. Pharmacogenet Genomics 2008; 18:91-7.

Kim EJ, Seo JW, Hwang JY, Han SS. Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs. Drug Chem Toxicol 2005; 28:177-86.

Kim EY, Lee SS, Jung HJ et al. Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. Clin Chim Acta 2010; 411:2043-8.

Kim EY, Suda T, Tanabe S, Batoev VB, Petrov EA, Iwata H. Evaluation of relative potencies for in vitro transactivation of the Baikal Seal aryl hydrocarbon receptor by dioxin-like compounds. Environ Sci Technol 2011; 45:1652-8.

Kim GH, Park K, Yeom SY et al. Characterization of ASC-2 as an antiatherogenic transcriptional coactivator of liver X receptors in macrophages. Mol Endocrinol 2009; 23:966-74.

Kim H, Bae SK, Park SJ et al. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. Br J Clin Pharmacol 2010; 70:126-31.

Kim H, Bartley GE, Rimando AM, Yokoyama W. Hepatic gene expression related to lower plasma cholesterol in hamsters fed high-fat diets supplemented with blueberry peels and peel extract. J Agric Food Chem 2010; 58:3984-91.

Kim H, Dionne RA. Lack of influence of GTP cyclohydrolase gene (GCH1) variations on pain sensitivity in humans. Mol Pain 2007; 3:6.

Kim H, Kang S, Kim H et al. In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. Rapid Commun Mass Spectrom 2006; 20:837-43.

Kim H, Marchuk DA, Pawlikowska L et al. Genetic considerations relevant to intracranial hemorrhage and brain arteriovenous malformations. Acta Neurochir Suppl 2008; 105:199-206.

Kim H, Seo KA, Kim H et al. Enzyme kinetic study of a new cardioprotective agent, KR-32570 using human liver microsomes and recombinant CYP isoforms. Arch Pharm Res 2007; 30:469-74.

Kim H, Turowski M, Anderson WH, Young SA, Kim Y, Yokoyama W. Supplementation of hydroxypropyl methylcellulose into yeast leavened all-whole grain barley bread potentiates cholesterol-lowering effect. J Agric Food Chem 2011; 59:7672-8.

Kim H, Yoon YJ, Kim H et al. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028. Toxicol Lett 2006; 166:105-14.

Kim HG, Hien TT, Han EH et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 2011; 162:1096-108.

Kim HG, Kishikawa S, Higgins AW et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 2008; 82:199-207.

Kim HJ, Choi JS. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Biopharm Drug Dispos 2005; 26:295-300.

Kim HJ, Harrington ME. Neuropeptide Y-deficient mice show altered circadian response to simulated natural photoperiod. Brain Res 2008; 1246:96-100.

Kim HJ, Jeong KH, Lee SH et al. Polymorphisms of the CTLA4 gene and kidney transplant rejection in Korean patients. Transpl Immunol 2010; 24:40-4.

Kim HJ, Lee JH, Kim SJ et al. Roles of NADPH oxidases in Cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 2010; 30:3933-46.

Kim HJ, Lee KW, Lee HJ. Protective effects of piceatannol against beta-amyloid-induced neuronal cell death. Ann N Y Acad Sci 2007; 1095:473-82.

Kim HJ, Park HY, Kim E et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica. Neurobiol Dis 2010; 37:349-55.

Kim HK, Jung HY, Lim S et al. A study of RET proto-oncogene polymorphisms in association with lung cancer risk in the Korean population. Anticancer Res 2010; 30:3621-7.

Kim HN, Yu L, Kim NY et al. Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J Hematol 2010; 85:822-4.

Kim HS, Kim MK, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009; 113:264-9.

Kim HS, Lee G, John SWM, Maeda N, Smithies O. Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc Nat Acad Sci USA 2002; 99:4602-7.

Kim HW, Chan Q, Afton SE et al. Human macrophage ATP7A is localized in the trans-Golgi apparatus, controls intracellular Copper levels, and mediates macrophage responses to dermal wounds. Inflammation 2011. doi:10. 1007/s10753-011-9302-z.

Kim IS, Kim DC, Kim HG et al. DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population. Cancer Genet Cytogenet 2010; 196:31-7.

Kim IS, Kim HG, Kim DC et al. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. Cancer Sci 2008; 99:2496-501.

Kim J, Castellano JM, Jiang H et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009; 64:632-44.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA. Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica 2011; 41:851-62.

Kim JC, Roh SA, Cho DH et al. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas. Anticancer Res 2009; 29:3115-23.

Kim JG, Chae YS, Sohn SK et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008; 1:62-6.

Kim JH, Cheon JH, Hong SS et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol 2010; 44:242-8.

Kim JH, Kim H, Lee KY et al. Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk. Lung Cancer 2007; 56:9-15.

Kim JH, Park SH, Bae SS et al. Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. J Pharmacol Exp Ther 2011; 338:451-7.

Kim JJ, Mandelli L, Lim S et al. Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008; 258:239-44.

Kim JJ, Mandelli L, Pae CU et al. Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:375-9.

Kim JJ, Shih JC, Chen K et al. Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice. Proc Natl Acad Sci USA 1997; 94:5929-33.

Kim JM, Stewart R, Kim SY et al. Synergistic associations of depression and apolipoprotein E genotype with incidence of dementia. Int J Geriatr Psychiatry 2011; 26:893-8.

Kim JR, Seo HB, Cho JY et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008; 66:802-10.

Kim JS, Yun CH. Inhibition of human cytochrome P450 3A4 activity by zinc(II) ion. Toxicol Lett 2005; 156:341-50.

Kim JW, Park HM, Choi YK, Chong SY, Oh D, Kim NK. Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients. Oncol Rep 2011; 25:167-72.

Kim JY, Ahn MR, Kim DK, Sheen YY. Histone deacetylase inhibitor stimulate CYP3A4 proximal promoter activity in HepG2 cells. Arch Pharm Res 2004; 27:407-14.

Kim JY, Baek M, Lee S et al. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4’-dimethoxy-5,6,5’,6’-dimethylenedioxybiphenyl-2,2’-dicarboxylate. Drug Metab Dispos 2001; 29:1555-60.

Kim JY, Lee S, Kim DH, Kim BR, Park R, Lee BM. Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes. J Toxicol Environ Health A 2002; 65:373-81.

Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 2008; 111:509-15.

Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 2004; 60:575-81.

Kim KA, Joo HJ, Park JY. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations. J Clin Pharm Ther 2010; 35:705-12.

Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol 2011; 67:129-34.

Kim KA, Kim MJ, Park JY et al. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 2003; 31:1227-34.

Kim KA, Lee JS, Park HJ et al. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes. Life Sci 2004; 74:2769-79.

Kim KA, Oh SO, Park PW, Park JY. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol 2005; 61:275-80.

Kim KA, Park JY, Lee JS, Lim S. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 2003; 26:631-7.

Kim KA, Park JY. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Drug Metab Dispos 2003; 31:1090-2.

Kim KA, Park JY. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol 2010; 66:721-5.

Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84:236-42.

Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47:87-93.

Kim KA, Park PW, Liu KH et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 2008; 48:66-72.

Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 2007; 63:53-8.

Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 2008; 64:589-97.

Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J Clin Pharm Ther 2010; 35:697-703.

Kim KA, Song WK, Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009; 86:511-8.

Kim KB, Seo KA, Yoon YJ et al. In vitro metabolism of a novel PPAR gamma agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s. Xenobiotica 2008; 38:1165-76.

Kim KH, Ahn T, Yun CH. Membrane properties induced by anionic phospholipids and phosphatidylethanolamine are critical for the membrane binding and catalytic activity of human cytochrome P450 3A4. Biochemistry 2003; 42:15377-87.

Kim KP, Jang G, Hong YS et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 2011; 104:605-12.

Kim KR, Cho SH, Choi SJ et al. TAP1 and TAP2 gene polymorphisms in Korean patients with allergic rhinitis. J Korean Med Sci 2007; 22:825-31.

Kim L, Kim do K, Yang WI et al. Overexpression of transforming growth factor-beta 1 in the valvular fibrosis of chronic rheumatic heart disease. J Korean Med Sci 2008; 1:41-8.

Kim M, Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract 2010; 4:191-5.

Kim M, Suh J, Romano D et al. Potential late-onset Alzheimer’s disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet 2009; 18:3987-96.

Kim MJ, Kim H, Cha IJ et al. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19:2651-8.

Kim MJ, Marchand P, Henegar C et al. Fate and complex pathogenic effects of dioxins and polychlorinated biphenyls in obese subjects before and after drastic weight loss. Environ Health Perspect 2011; 119:377-83.

Kim MK, Lee SH, Park MS et al. Mutation screening in Korean hypokalemic periodic paralysis patients: a novel SCN4A Arg672Cys mutation. Neuromuscul Disord 2004; 14:727-31.

Kim NS, Ko MM, Cha MH, Oh SM, Bang OS. Age and sex dependent genetic effects of neuropeptide Y promoter polymorphism on susceptibility to ischemic stroke in Koreans. Clin Chim Acta 2010; 411:1243-7.

Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-99.

Kim S, Chang WE, Kumar R, Klimov DK. Naproxen interferes with the assembly of Aβ oligomers implicated in Alzheimer’s disease. Biophys J 2011; 100:2024-32.

Kim S, Dinchuk JE, Anthony MN et al. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction. Drug Metab Dispos 2010; 38:16-24.

Kim S, Pyun JA, Cha DH, Ko JJ, Kwack K. Epistasis between FSHR and CYP19A1 polymorphisms is associated with premature ovarian failure. Fertil Steril 2011; 95:2585-8.

Kim S, Pyun JA, Kang H, Kim J, Cha DH, Kwack K. Epistasis between CYP19A1 and ESR1 polymorphisms is associated with premature ovarian failure. Fertil Steril 2011; 95:353-6.

Kim S, Swaminathan S, Shen L et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011; 76:69-79.

Kim SA, Kim JH, Park M, Cho IH, Yoo HJ. Family-based association study between GRIK2 polymorphisms and autism spectrum disorders in the Korean trios. Neurosci Res 2007; 58:332-5.

Kim SG, Kim CM, Choi SW et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 2009; 201:611-8.

Kim SG, Lee AJ, Lee SJ, Suh HS, Shin IH. Inhibition of P-glycoprotein facilitated glycosaminoglycan accumulation during chondrogenesis of human bone marrow mesenchymal stem cells. Int J Rheum Dis 2011; 14:199-205.

Kim SH, Bae JS, Suh CH, Nahm DH, Holloway JW, Park HS. Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy 2005; 60:760-5.

Kim SH, Choi JH, Park HS et al. Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 2005; 35:585-90.

Kim SH, Hur GY, Choi JH, Park HS. Pharmacogenetics of aspirin-intolerant asthma. Pharmacogenomics 2008; 9:85-91.

Kim SH, Kim SH, Bahn JW et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10:1767-79.

Kim SH, Kim SH, Yoon HJ et al. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. Eur J Clin Pharmacol 2011; 67:121-7.

Kim SH, Kim YK, Park HW et al. Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma. Pharmacogenet Genomics 2007; 17:295-304.

Kim SH, Park HS. Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J 2006; 47:15-21.

Kim SH, Ye YM, Hur GY et al. Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment. Yonsei Med J 2009; 50:182-8.

Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS. Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010; 10:280-90.

Kim SJ, Gonen D, Hanna GL, Leventhal BL, Cook EH Jr. Deletion polymorphism in the coding region of the human NESP55 alternative transcript of GNAS1. Mol Cell Probes 2000; 14:191-4.

Kim SJ, Kang HS, Jung SY et al. Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J Mol Med 2010; 88:1123-31.

Kim SK, Lee SI, Shin CJ, Son JW, Ju G. The genetic factors affecting drinking behaviors of korean young adults with variant aldehyde dehydrogenase 2 genotype. Psychiatry Investig 2010; 7:270-7.

Kim SM, Chin HJ, Oh YK, Kim YS, Kim S, Lim CS. Blood pressure-related genes and the progression of IgA nephropathy. Nephron Clin Pract 2009; 113:301-8.

Kim SR, Nakamura T, Saito Y et al. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab Pharmacokinet 2003; 18:327-32.

Kim SR, Saito Y, Maekawa K et al. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet 2008; 23:379-84.

Kim T, Park H, Yue W et al. Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland. Breast Cancer Res Treat 2011; 126:779-89.

Kim TH, Lee SH, Lee SM. Role of Kupffer cells in pathogenesis of sepsis-induced drug metabolizing dysfunction. FEBS J 2011; 278:2307-17.

Kim TW, Febbraio M, Robinet P et al. The critical role of IL-1 receptor-associated kinase 4-mediated NF-κB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis. J Immunol 2011; 186:2871-80.

Kim WJ, Lee JH, Yi J et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 2010; 20:249-56.

Kim WJ, Oh YM, Sung J et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008; 186:381-6.

Kim WJ, Sheen SS, Kim TH et al. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respirology 2009; 14:260-3.

Kim WS, Bhatia S, Elliott DA et al. Increased ATP-binding cassette transporter A1 expression in Alzheimer’s disease hippocampal neurons. J Alzheimers Dis 2010; 21:193-205.

Kim WS, Chan SL, Hill AF, Guillemin GJ, Garner B. Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J Alzheimers Dis 2009; 16:121-31.

Kim Y, Park K, Kang W. Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits. Biopharm Drug Dispos 2010; 31:443-9.

Kim Y, Roh S, Park JY, Kim Y, Cho DH, Kim JC. Differential expression of the LOX family genes in human colorectal adenocarcinomas. Oncol Rep 2009; 22:799-804.

Kim YD, Eom SY, Ogawa M et al. Ethanol-induced oxidative DNA damage and CYP2E1 expression in liver tissue of Aldh2 knockout mice. J Occup Health 2007; 49:363-9.

Kim YD, Oyama T, Isse T, Kim H, Kawamoto T. Expression levels of hepatic cytochrome P450 enzymes in Aldh2-deficient mice following ethanol exposure: a pilot study. Arch Toxicol 2005; 79:192-5.

Kim YH, Nobusawa S, Mittelbronn M et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010; 177:2708-14.

Kim YW, Kim YK, Kim DK, Sheen YY. Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor. Xenobiotica 2008; 38:451-64.

Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002; 62:1-6.

Kimchi-Sarfaty C, Oh JM, Kim IW et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-8.

Kimmel SE, Christie J, Kealey C et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 2008; 8:53-60.

Kimoto T, Ishii H, Higo S, Hojo Y, Kawato S. Semicomprehensive analysis of the postnatal age-related changes in the mRNA expression of sex steroidogenic enzymes and sex steroid receptors in the male rat hippocampus. Endocrinology 2010; 151:5795-806.

Kimouli M, Gourvas V, Konstantoudaki X, Basta M, Miyakis S, Spandidos DA. The effect of an exon 12 polymorphism of the human thromboxane synthase (CYP5A1) gene in stroke patients. Med Sci Monit 2009; 15:30-5.

Kimpfler S, Sevko A, Ring S et al. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 2009; 183:6330-7.

Kimura M, Yamazaki H, Fujieda M et al. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos 2005; 33:1361-6.

Kimura R, Miyashita K, Kokubo Y et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120:181-6.

Kimura S, Oshima K, Okuda S et al. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45:1088-94.

Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-904.

Kimura T, Okumura F, Onodera A, Nakanishi T, Itoh N, Isobe M. Chromium (VI) inhibits mouse metallothionein-I gene transcription by modifying the transcription potential of the co-activator p300. J Toxicol Sci 2011; 36:173-80.

Kimura T, Shono M, Yakota S et al. Apolipoprotein E-4 and tardive dyskinesia in a Japanese population. J Psychiatry 2000; 34:329-32.

Kimura T, Yokota S, Igata-Yi R, Shono M, Takamatsu J, Miyakawa T. Apolipoprotein e2 allele and early onset schizophrenia. Neurosci Lett 1997; 231:53-5.

Kimura Y, Ito H, Hatano T. Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol Pharm Bull 2010; 33:1977-82.

Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 2010; 48:429-35.

Kindmark A, Jawaid A, Harbron CG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8:186-95.

King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004; 14:813-22.

King CR, Xiao M, Yu J et al. Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 2007; 63:547-54.

King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22:1709-17.

King LM, Gainer JV, David GL et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 2005; 15:7-13.

King LM, Ma J, Srettabunjong S et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002; 61:840-52.

King VL, Lin AY, Kristo F et al. Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation 2009; 119:426-35.

Kinirons MT, Lang CC, He HB et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996; 41:69-72.

Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57:540-4.

Kinnula K, Linnainmaa K, Raivio KO, Kinnula VL. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br J Cancer 1998; 77:1097-102.

Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol 2005; 18:1868-75.

Kinoshita K, Nakagawa K, Hamada J et al. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Int J Oncol 2010; 37:869-77.

Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011; 33:213-24.

Kinoshita Y, Matsumoto N, Watanabe M et al. Comparison of the effects of omeprazole and rabeprazole on ticlopidine metabolism in vitro. J Pharmacol Sci 2011; 117:19-26.

Kirby DM, McFarland R, Ohtake A et al. Mutations of the mitochondrial ND1 gene as a cause of MELAS. J Med Genet 2004; 41:784-9.

Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, Alaoui-Jamali MA. Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 1996; 24:458-67.

Kirby GM, Wolf CR, Neal GE et al. In vitro metabolism of aflatoxin B1 by normal and tumorous liver tissue from Thailand. Carcinogenesis 1993; 14:2613-20.

Kirby LC, Johnson BM, Adams LM et al. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin. J Clin Pharmacol 2010; 50:566-75.

Kircher T, Markov V, Krug A et al. Association of the DTNBP1 genotype with cognition and personality traits in healthy subjects. Psychol Med 2009; 39:1657-65.

Kirches E, Scherlach C, von Bossanyi P et al. MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas. Clin Neuropathol 1999; 18:1-8.

Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12:101-9.

Kirchheiner J, Brockmöller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71:286-96.

Kirchheiner J, Brøsen K, Dahl ML et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173-92.

Kirchheiner J, Heesch C, Bauer S et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004; 76:302-12.

Kirchheiner J, Henckel HB, Franke L et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 2005; 15:579-87.

Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmöller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004; 24:647-52.

Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmöller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008; 28:78-83.

Kirchheiner J, Kudlicz D, Meisel C et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74:186-94.

Kirchheiner J, Lorch R, Lebedeva E et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008; 9:841-6.

Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmöller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72:62-75.

Kirchheiner J, Meineke I, Fuhr U, Rodríguez-Antona C, Lebedeva E, Brockmöller J. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 2008; 9:277-88.

Kirchheiner J, Meineke I, Müller G et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet 2004; 43:267-78.

Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12:571-80.

Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmöller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55:51-61.

Kirchheiner J, Rodríguez-Antona C. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs 2009; 23:181-91.

Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44:1209-25.

Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmöller J. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics 2003; 13:721-8.

Kirchheiner J, Schmidt H, Tzvetkov M et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7:257-65.

Kirchheiner J, Seeringer A, Godoy AL et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 2011; 16:333-41.

Kirchheiner J, Störmer E, Meisel C, Steinbach N, Roots I, Brockmöller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13:473-80.

Kirchheiner J, Thomas S, Bauer S et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006; 80:657-67.

Kirchheiner J, Ufer M, Walter EC et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14:19-26.

Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43:83-95.

Kiriazis H, Wang K, Xu Q et al. Knockout of beta(1)- and beta(2)-adrenoceptors attenuates pressure overload-induced cardiac hypertrophy and fibrosis. Br J Pharmacol 2008; 153:684-92.

Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009; 200:53-61.

Kiriyama A, Nishiura T, Yamaji H, Takada K. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother 1999; 43:549-56.

Kirkpatrick RB, Parveen Z, Martin PF. Isolation of silencer-containing sequences causing a tissue-specific position effect on alcohol dehydrogenase expression in Drosophila melanogaster. Dev Genet 1994; 15:188-200.

Kirschbaum KM, Müller MJ, Malevani J et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008; 9:212-8.

Kirschbaum KM, Uhr M, Holthoewer D et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010; 59:474-9.

Kirschner K, Singh R, Prost S, Melton DW. Characterisation of Ercc1 deficiency in the liver and in conditional Ercc1-deficient primary hepatocytes in vitro. DNA Repair 2007; 6:304-16.

Kirshbom PM, Mahle WT, Joyner RW et al. The endothelin-1 G5665T polymorphism impacts transplant-free survival for single ventricle patients. J Thorac Cardiovasc Surg 2008; 136:117-22.

Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47:298-303.

Kiser JJ, Carten ML, Aquilante CL et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83:265-72.

Kisfali P, Mohás M, Maász A et al. Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2010; 20:505-11.

Kishi R, Sata F, Yoshioka E et al. Exploiting gene-environment interaction to detect adverse health effects of environmental chemicals on the next generation. Basic Clin Pharmacol Toxicol 2008; 102:191-203.

Kishi S, Cheng C, French D et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109:4151-7.

Kishi S, Yang W, Boureau B et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004; 103:67-72.

Kishi T, Ikeda M, Kitajima T et al. Alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. Ann N Y Acad Sci 2008; 1139:70-82.

Kishi T, Ikeda M, Kitajima T et al. Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population. J Neural Transm 2008; 115:1457-61.

Kishi T, Okochi T, Tsunoka T et al. Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. Psychiatry Res 2011; 185:20-6.

Kishi T, Tsunoka T, Ikeda M et al. Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. J Hum Genet 2009; 54:629-33.

Kishimoto R, Ogishi Y, Ueda M et al. Gender-related differences in mouse hepatic ethanol metabolism. J Nutr Sci Vitaminol 2002; 48:216-24.

Kishimoto R, Ueda M, Yoshinaga H, Goda K, Park SS. Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice. J Nutr Sci Vitaminol 1999; 45:275-86.

Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997; 98:273-92.

Kishimoto W, Hiroi T, Shiraishi M et al. Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology 2004; 145:699-705.

Kishino S, Ogawa M, Takekuma Y et al. The variability of liver graft function and urinary 6beta-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients. Clin Transplant 2004; 18:124-9.

Kisiel BM, Kosinska J, Wierzbowska M et al. Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta. Lupus 2011; 20:85-9.

Kisor DF. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. Ann Pharmacother 2005; 39:1056-63.

Kistler A, Liechti H, Pichard L, Wolz E, Oesterhelt G, Hayes A, Maurel P. Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch Toxicol 2002; 75:665-75.

Kita H, Carmichael J, Swartz J et al. Modulation of polyglutamine-induced cell death by genes identified by expression profiling. Hum Molec Genet 2002; 11:2279-87.

Kita T, Sakaeda T, Baba T et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003; 26:386-90.

Kitagawa K, Kunugita N, Kitagawa M, Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 2001; 276:17830-5.

Kitamoto T, Ohta M, Doh-ura K, Hitoshi S, Terao Y, Tateishi J. Novel missense variants of prion protein in Creutzfeldt-Jakob disease or Gerstmann-Staussler syndrome. Biochem Biophys Res Commun 1993; 191:709-14.

Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 2005; 26:59-65.

Kitamura R, Matsuoka K, Nagayama S, Otagiri M. Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68. Drug Metab Pharmacokinet 2008; 23:421-7.

Kitamura S, Sugihara K, Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 2006; 21:83-98.

Kitamura Y, Kusuhara H, Sugiyama Y. Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine. J Pharmacol Exp Ther 2010; 332:659-66.

Kitazawa T, Asakawa K, Nakamura T et al. M3 muscarinic receptors mediate positive inotropic responses in mouse atria: a study with muscarinic receptor knockout mice. J Pharmacol Exp Ther 2009; 330:487-93.

Kitsios G, Zintzaras E. Genetic variation associated with ischemic heart failure: a HuGE review and meta-analysis. Am J Epidemiol 2007; 166:619-33.

Kitsios G, Zintzaras E. ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet 2009; 10:50.

Kitsios GD, Zintzaras E. Synopsis and data synthesis of genetic association studies in hypertension for the adrenergic receptor family genes: the CUMAGAS-HYPERT database. Am J Hypertens 2010; 23:305-13.

Kittles RA, Chen W, Panguluri RK et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 2002; 110:553-60.

Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42:387-9.

Kivistö KT, Griese EU, Fritz P et al. Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn Schmiedebergs Arch Pharmacol 1996; 353:207-12.

Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46:49-53.

Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40:523-30.

Kivistö KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37(1 Suppl):40-8.

Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997; 62:348-54.

Kivistö KT, Lilja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66:448-53.

Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004; 18:621-6.

Kivistö KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007; 24:239-47.

Kivistö KT, Wang JS, Backman JT et al. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 2001; 57:37-42.

Kiyohara C, Miyake Y, Koyanagi M et al. APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson’s disease in a Japanese population. J Neural Transm 2011; 118:1335-44.

Kiyohara C, Washio M, Horiuchi T et al. Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population. J Rheumatol 2009; 36:2195-203.

Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 2006; 17:89-99.

Kiyotani K, Fujieda M, Yamazaki H et al. Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab Pharmacokinet 2002; 17:482-7.

Kiyotani K, Mushiroda T, Imamura CK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010; 28:1287-93.

Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008; 99:967-72.

Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99:995-9.

Kiyotani K, Shimizu M, Kumai T, Kamataki T, Kobayashi S, Yamazaki H. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. Eur J Clin Pharmacol 2010; 66:1065-8.

Kiyotani K, Yamazaki H, Fujieda M et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 2003; 13:689-95.

Kjærstad MB, Nielsen F, Nøhr-Jensen L, Zwisler S, Brøsen K, Andersen HR. Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. Eur J Clin Pharmacol 2010; 66:1189-97.

Kjærstad MB, Taxvig C, Nellemann C, Vinggaard AM, Andersen HR. Endocrine disrupting effects in vitro of conazole antifungals used as pesticides and pharmaceuticals. Reprod Toxicol 2010; 30:573-82.

Kjellander B, Masimirembwa CM, Zamora I. Exploration of enzyme-ligand interactions in CYP2D6 & 3A4 homology models and crystal structures using a novel computational approach. J Chem Inf Model 2007; 47:1234-47.

Klappe K, Hummel I, Hoekstra D, Kok JW. Lipid dependence of ABC transporter localization and function. Chem Phys Lipids 2009; 161:57-64.

Klapper M, Böhme M, Nitz I, Döring F. Type 2 diabetes-associated fatty acid binding protein 2 promoter haplotypes are differentially regulated by GATA factors. Hum Mutat 2008; 29:142-9.

Klass DM, Lauer N, Hay B, Kratzer W, Fuchs M; EMIL Study Group. Arg64 variant of the beta3-adrenergic receptor is associated with gallstone formation. Am J Gastroenterol 2007; 102:2482-7.

Klaver D, Hung AC, Gasperini R, Foa L, Aguilar MI, Small DH. Effect of heparin on APP metabolism and Abeta production in cortical neurons. Neurodegener Dis 2010; 7:187-9.

Kleemann R, Verschuren L, Morrison M et al. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011; 218:44-52.

Klees TM, Sheffels P, Dale O, Kharasch ED. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos 2005; 33:303-11.

Klees TM, Sheffels P, Thummel KE, Kharasch ED. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology 2005; 102:550-6.

Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005; 2:355-65.

Kleibl Z, Fidlerova J, Kleiblova P et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 2009; 56:303-16.

Klein C, Brin MF, Kramer P et al. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci USA 1999; 96:5173-6.

Klein C, Gurvich N, Sena-Esteves M et al. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Ann Neurol 2000; 47:369-73.

Klein K, Lang T, Saussele T et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-73.

Klein K, Tatzel S, Raimundo S et al. A natural variant of the heme-binding signature(R441C) resulting in complete loss of function of CYP2D6. Drug Metab Dispos 2007; 35:1247-50.

Klein ML, Francis PJ, Rosner B et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008; 115:1019-25.

Klein TE, Chang JT, Cho MK et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001; 1:167-70.

Klemm M, Eidens M, Lorenz M et al. Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders? Clin Lab 2010; 56:473-80.

Klempan T, Hudon-Thibeault AA, Oufkir T, Vaillancourt C, Sanderson JT. Stimulation of serotonergic 5-HT(2A) receptor signaling increases placental aromatase (CYP19) activity and expression in BeWo and JEG-3 human choriocarcinoma cells. Placenta 2011; 32:651-6.

Klepstad P, Fladvad T, Skorpen F et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011; 152:1139-45.

Klerk M, Verhoef P, Clarke R et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288:2023-31.

Klerkx AHEM, Tanck MWT, Kastelein JJP et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Molec Genet 2003; 12:111-23.

Klibanov OM. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs 2009; 10:845-59.

Klieber S, Hugla S, Ngo R et al. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 2008; 36:851-62.

Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002; 23:687-702.

Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 2003; 133(7 Suppl):2444-7.

Klimkowicz-Mrowiec A, Wołkow P, Spisak K et al. Interleukin-6 gene (-174 C/G ) and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population. Neurol Neurochir Pol 2010; 44:537-41.

Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R. Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genet Cytogenet 2009; 195:143-9.

Klinghoffer RA, Mueting-Nelsen PF, Faerman A, Shani M, Soriano P. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol Cell 2001; 7:343-54.

Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73:232-41.

Kloeckener-Gruissem B, Barthelmes D, Labs S et al. Genetic association with response to intravitreal ranibizumab in neovascular AMD patients. Invest Ophthalmol Vis Sci 2011; 52:4694-702.

Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13:289-95.

Klotsman M, Weinberg CR, Davis K, Binnie CG, Hartmann KE. A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH. Pharmacogenomics J 2004; 4:251-9.

Klotsman M, York TP, Pillai SG et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189-96.

Klotz L, Schmidt S, Heun R, Klockgether T, Kölsch H. Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis. Neurosci Lett 2009; 449:81-3.

Klotz U. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung 2002; 52:155-61.

Klotz U. Pharmacological comparison of the statins. Arzneimittelforschung 2003; 53:605-11.

Klotz U. Tramadol-the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003; 53:681-7.

Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44:297-302.

Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 2007; 46:985-96.

Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41:67-76.

Klotz U, Ammon E. Clinical and toxicological consequences of the inductive potential of ethanol. Eur J Clin Pharmacol 1998; 54:7-12.

Kluijtmans LA, van den Heuvel LP, Boers GH et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58:35-41.

Kluijtmans LA, Young IS, Boreham CA et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101:2483-8.

Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging 1995; 16:541-8.

Klupa T, Skupien J, Mirkiewicz-Sieradzka B et al. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. Diabetes Technol Ther 2010; 12:387-91.

Kluth D, Banning A, Paur I, Blomhoff R, Brigelius-Flohé R. Modulation of pregnane X receptor- and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds. Free Radic Biol Med 2007; 42:315-25.

Kluth D, Landes N, Pfluger P et al. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic Biol Med 2005; 38:507-14.

Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2011; 50:281-94.

Knappenberger KS, Tian G, Ye X et al. Mechanism of gamma-secretase cleavelage activation: is gamma-secretase regulated throught autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry 2004; 43:6208-18.

Knebel W, Rao N, Uchimura T et al. Population pharmacokinetic analysis of Istradefylline in healthy subjects and in patients with Parkinson’s disease. J Clin Pharmacol 2011; 51:40-52.

Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162:1010-2.

Knight PG, Satchell L, Glister C. Intra-ovarian roles of activins and inhibins. Mol Cell Endocrinol 2011. doi:10. 1016/j. mce. 2011. 04. 024.

Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 2009; 68:402-12.

Knisely AS, Strautnieks SS, Meier Y et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 2006; 44:478-86.

Knoblauch H, Bauerfeind A, Toliat MR et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 2004; 13:993-1004.

Knockaert L, Descatoire V, Vadrot N, Fromenty B, Robin MA. Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol In Vitro 2011; 25:475-84.

Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991; 101:1680-91.

Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998; 32:1299-302.

Knoll B, Hach-Wunderle V, Rieger S, Häring D, Mannhalter C. Combined occurrence of a heterozygous missense mutation in the protein C gene and allelic exclusion of one protein S allele leading to severe venous thrombosis. Thromb Res 2001; 103:3-8.

Knöller AS, Blakeslee JJ, Richards EL, Peer WA, Murphy AS. Brachytic2/ZmABCB1 functions in IAA export from intercalary meristems. J Exp Bot 2010; 61:3689-96.

Knouff C, Briand O, Lestevel S, Clavey V, Altenburg M, Maeda N. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor. Biochem Biophys Acta 2004; 1684:8-17.

Knouff C, Malloy S, Wilder J, Altenburg MK, Maeda N. Doubling expression of the low density lipoprotein receptor by truncation of the 3-prime-untranslated region sequence ameliorates type III hyperlipoproteinemia in mice expressing the Human ApoE2 isoform. J Biol Chem 2001; 276:3856-62.

Knouff CW, Lim N, Song K et al. Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes. Pharmacogenet Genomics 2008; 18:1051-7.

Knüpfer H, Knüpfer MM, Hotfilder M, Preiss R. P450-expression in brain tumors. Oncol Res 1999; 11:523-8.

Knüpfer H, Schmidt R, Stanitz D, Brauckhoff M, Schönfelder M, Preiss R. CYP2C and IL-6 expression in breast cancer. Breast 2004; 13:28-34.

Ko B, Hoover RS. Molecular physiology of the thiazide-sensitive sodium-chloride cotransporter. Curr Opin Nephrol Hypertens 2009; 18:421-7.

Ko E, Lee J, Lee H. Essential role of brc-2 in chromosome integrity of germ cells in C. elegans. Mol Cells 2008; 26:590-4.

Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 2000l; 49:343-51.

Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25:853-62.

Ko T, Kakizoe Y, Wakida N et al. Regulation of adrenal aldosterone production by serine protease prostasin. J Biomed Biotechnol 2010. doi:10. 1155/2010/793843.

Kobashi G, Hata A, Ohta K et al. A1166C variant of angiotensin II type 1 receptor gene is associated with severe hypertension in pregnancy independently of T235 variant of angiotensinogen gene. J Hum Genet 2004; 49:182-6.

Kobashi G, Yamada H, Asano T et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women. Am J Med Genet 2000; 93:122-5.

Kobashi G, Yamada H, Ohta K, Kato E, Ebina Y, Fujimoto S. Endothelial nitric oxide synthase gene (NOS3) variant and hypertension in pregnancy. Am J Med Genet 2001; 103:241-4.

Kobayashi A, Naito S, Enomoto H et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 2007; 131:563-70.

Kobayashi K, Abe S, Nakajima M et al. Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab Dispos 1999; 27:1429-33.

Kobayashi K, Chiba K, Yagi T et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280:927-33.

Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27:763-6.

Kobayashi K, Mimura N, Fujii H et al. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 2000; 6:3297-303.

Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, Chiba K. Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 1999; 27:860-5.

Kobayashi K, Yamamoto T, Chiba K et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26:818-21.

Kobayashi M, Kishimoto N, Ohnishi H et al. beta 2-adrenoceptor polymorphism and effect of inhaled beta 2-stimulant (procaterol) on airway resistance measured by body plethysmography in healthy volunteers. Nihon Kokyuki Gakkai Zasshi 2002; 40:637-43.

Kobayashi M, Otani T, Iwasaki M et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan. Gastric Cancer 2009; 12:198-205.

Kobayashi M, Otani T, Iwasaki M et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of colorectal cancer: a hospital-based case-control study in Japan. Scand J Gastroenterol 2009; 44:952-9.

Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Eng J Med 2005; 352:786-92.

Kobayashi S, Tateno M, Park TW et al. Apolipoprotein e4 frequencies in a Japanese population with Alzheimer’s disease and dementia with lewy bodies. PLoS One 2011. doi:10. 1371/journal. pone. 0018569.

Kobayashi T, Homma M, Momo K, Kobayashi D, Kohda Y. A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition. Biomed Chromatogr 2011; 25:435-8.

Kobayashi Y, Horiguchi R, Nozu R, Nakamura M. Expression and localization of forkhead transcriptional factor 2 (Foxl2) in the gonads of protogynous wrasse, Halichoeres trimaculatus. Biol Sex Differ 2010; 1:3.

Kobayashi Y, Momoi MY, Tominaga K. Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-Leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Am J Hum Genet 1991; 49:590-9.

Kobayashi Y, Nozu R, Nakamura M. Role of estrogen in spermatogenesis in initial phase males of the three-spot wrasse (Halichoeres trimaculatus): effect of aromatase inhibitor on the testis. Dev Dyn 2011; 240:116-21.

Kobayashi Y, Ohbayashi M, Kohyama N, Yamamoto T. Mouse organic anion transporter 2 and 3 (mOAT2/3[Slc22a7/8]) mediates the renal transport of bumetanide. Eur J Pharmacol 2005; 524:44-8.

Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005; 57:573-8.

Kobayashi Y, Ota S, Tanaka K et al. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann Neurol 2003:133-7.

Kobayashi Y, Seino K, Hosonuma S et al. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. Gynecol Oncol 2011; 121:390-4.

Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John’s wort drug interactions. Curr Drug Metab 2008; 9:1027-37.

Köblös G, Andrikovics H, Prohászka Z, Tordai A, Váradi A, Arányi T. The R1141X loss-of-function mutation of the ABCC6 gene is a strong genetic risk factor for coronary artery disease. Genet Test Mol Biomarkers 2010; 14:75-8.

Kocabas NA, Aksoy P, Pelleymounter LL et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008; 36:1951-9.

Kocabas NA, Antonijevic I, Faghel C et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 2011; 26:1-10.

Kocabas NA, Faghel C, Barreto M et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int Clin Psychopharmacol 2010; 25:218-27.

Kocisko DA, Come JH, Priola SA et al. Cell-free formation of protease-resistant prion protein. Nature 1994; 370:471-4.

Koch CA, Huang SC, Moley JF et al. Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene 2001; 20:7809-11.

Koch I, Weil R, Wolbold R et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30:1108-14.

Kochethu G, Delgado J, Pepper C et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 2006; 30:1113-8.

Kochi Y, Suzuki A, Yamada R, Yamamoto K. Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun 2009; 32:158-62.

Koda Y, Soejima M, Yoshioka N, Kimura H. The haptoglobin-gene deletion responsible for anhaptoglobinemia. Am J Hum Genet 1998; 62:245-52.

Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 2010; 333:788-96.

Kodama M, Kitadai Y, Sumida T et al. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 2010; 101:1984-9.

Kodama S, Moore R, Yamamoto Y, Negishi M. Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. Biochem J 2007; 407:373-81.

Koehler SC, von Ahsen N, Schlumbohm C et al. Marmoset CYP3A21, a model for human CYP3A4: protein expression and functional characterization of the promoter. Xenobiotica 2006; 36:1210-26.

Koehn J, Fountoulakis M, Krapfenbauer K. Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance. Infect Disord Drug Targets 2008; 8:109-18.

Koeppel F, Poindessous V, Lazar V, Raymond E, Sarasin A, Larsen AK. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res 2004; 10:5604-13.

Koers H. Priapism caused by simultaneous use of zuclopentixol and paroxetine. Ned Tijdschr Geneeskd 1999; 143:208-10.

Kofla G, Turner V, Schulz B et al. Doxorubicin induces drug efflux pumps in Candida albicans. Med Mycol 2011; 49:132-42.

Koga N, Ohta C, Kato Y et al. In vitro metabolism of nobiletin, a polymethoxy-flavonoid, by human liver microsomes and cytochrome P450. Xenobiotica 2011; 41:927-33.

Koh J, Dar M, Untch BR et al. Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor. Mol Endocrinol 2011; 25:867-76.

Koh JM, Kim BJ, Kim SY et al. Association of Paraoxonase 1 (PON1) polymorphisms with osteoporotic fracture risk in postmenopausal Korean women. Exp Mol Med 2011; 43:71-81.

Koh KH, Xie H, Yu AM, Jeong H. Altered cytochrome P450 expression in mice during pregnancy. Drug Metab Dispos 2011; 39:165-9.

Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 2004; 90:1760-4.

Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 2005; 26:459-64.

Koh WP, Yuan JM, Wang R et al. Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma. Cancer 2011; 117:3383-92.

Kohalmy K, Tamási V, Kóbori L et al. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab Dispos 2007; 35:1495-501.

Kohen R, Shofer JB, Korvatska O et al. ABCB1 genotype and CSF {beta}-Amyloid in Alzheimer disease. J Geriatr Psychiatry Neurol 2011; 24:63-6.

Kohli MA, Salyakina D, Pfennig A et al. Association of genetic variants in the neurotrophic receptor-encoding gene NTRK2 and a lifetime history of suicide attempts in depressed patients. Arch Gen Psychiatry 2010; 67:348-59.

Kohli U, Hahn MK, English BA et al. Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans. Pharmacogenet Genomics 2011; 21:171-8.

Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 2010; 69:95-8.

Kohlrausch FB, Gama CS, Lobato MI et al. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet Genomics 2008; 18:599-609.

Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 2008; 9:1429-36.

Köhnke MD, Griese EU, Stösser D, Gaertner I, Barth G. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002; 35:116-8.

Köhnke MD, Lutz U, Wiatr G et al. Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone. Eur J Clin Pharmacol 2006; 62:333-4.

Kohno T, Kakinuma R, Iwasaki M et al. Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs. Carcinogenesis 2010; 31:1794-9.

Kohno T, Kunitoh H, Shimada Y et al. Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis 2010; 31:834-41.

Koide T, Ohtake H, Nakajima T et al. A patient with dementia with Lewy bodies and codon 232 mutation of PRNP. Neurology 2002; 59:1619-21.

Kojima K, Nagata K, Matsubara T, Yamazoe Y. Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes. Drug Metab Pharmacokinet 2007; 22:276-86.

Kojima M, Ashino T, Yoshida T, Iwakura Y, Sekimoto M, Degawa M. IL-1 regulates the Cyp7a1 gene and serum total cholesterol level at steady state in mice. Biochem Biophys Res Commun 2009; 379:239-42.

Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, Watanabe H. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. J Clin Pharmacol 2009; 49:568-73.

Kolars JC, Lown KS, Schmiedlin-Ren P et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4:247-59.

Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90:1871-8.

Kolek MJ, Carlquist JF, Muhlestein JB et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148:1034-40.

Kolesar J, Brundage RC, Pomplun M et al. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemother Pharmacol 2011; 67:393-400.

Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002; 21:1119-24.

Kolilekas L, Anagnostopoulos GK, Lampaditis I, Eleftheriadis I. Potential interaction between telithromycin and warfarin. Ann Pharmacother 2004; 38:1424-7.

Kolitz JE, George SL, Marcucci G et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010; 116:1413-21.

Kolokythas A, Schwartz JL, Pytynia KB et al. Analysis of RNA from brush cytology detects changes in B2M, CYP1B1 and KRT17 levels with OSCC in tobacco users. Oral Oncol 2011; 47:532-6.

Kolouchova G, Brcakova E, Hirsova P et al. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. J Gastroenterol Hepatol 2011; 26:1544-51.

Kölsch H, Larionov S, Dedeck O et al. Association of the glutathione S-transferase omega-1 Ala140Asp polymorphism with cerebrovascular atherosclerosis and plaque-associated interleukin-1 alpha expression. Stroke 2007; 38:2847-50.

Kölsch H, Linnebank M, Lütjohann D et al. Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke. Neurology 2004; 63:2255-60.

Kolukisaoglu Ü, Wendler C, Goerdes D, Diener A, Thurow K. Inhibitory effects of phthalimide derivatives on the activity of the hepatic cytochrome P450 monooxygenases CYP2C9 and CYP2C19. J Enzyme Inhib Med Chem 2010; 25:876-86.

Kolwankar D, Vuppalanchi R, Ethell B et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol 2007; 5:388-93.

Kolz M, Baumert J, Gohlke H et al. Association study between variants in the fibrinogen gene cluster, fibrinogen levels and hypertension: results from the MONICA/KORA study. Thromb Haemost 2009; 101:317-24.

Kollberg G, Jansson M, Perez-Bercoff A et al. Low frequency of mtDNA point mutations in patients with PEO associated with POLG1 mutations. Europ J Hum Genet 2005; 13:436-69.

Kollmann K, Heller G, Ott RG et al. C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5’ region of Cdk6. Blood 2011; 117:4065-75.

Komatsu T, Honda K, Kubota A, Kitazawa T, Hiraga T, Teraoka H. Molecular cloning and expression of cytochrome P450 2D6 in the livers of domestic cats. J Vet Med Sci 2010; 72:1633-6.

Komatsu T, Yamazaki H, Asahi S et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos 2000; 28:1361-8.

Komatsu T, Yamazaki H, Nakajima M, Yokoi T. Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes. Biochem Pharmacol 2002; 63:2081-90.

Komen JC, Wanders RJ. Identification of the cytochrome P450 enzymes responsible for the omega-hydroxylation of phytanic acid. FEBS Lett 2006; 580:3794-8.

Komina O, Nosske E, Maurer M, Wesierska-Gadek J. Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells. J Exp Ther Oncol 2011; 9:27-35.

Kominami S, Tanabe N, Ota M et al. HLA-DPB1 and NFKBIL1 may confer the susceptibility to chronic thromboembolic pulmonary hypertension in the absence of deep vein thrombosis. J Hum Genet 2009; 54:108-14.

Komloova M, Musilek K, Dolezal M, Gunn-Moore F, Kuca K. Structure-activity relationship of quaternary acetylcholinesterase inhibitors – outlook for early myasthenia gravis treatment. Curr Med Chem 2010; 17:1810-24.

Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R. Effect of the St. John’s wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 2005; 11:6972-9.

Komoroski BJ, Zhang S, Cai H et al. Induction and inhibition of cytochromes P450 by the St. John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32:512-8.

Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2008; 97:1775-800.

Komura H, Yasuda M, Yoshida NH, Sugiyama Y. Species difference in nisoldipine oxidation activity in the small intestine. Drug Metab Pharmacokinet 2002; 17:427-36.

Konda B, Tiwari RN, Fegade H. Development and validation of stability indicating method for the determination of exemestane by reverse phase high performance liquid chromatography. J Chromatogr Sci 2011; 49:634-9.

Kondo DG, Speer MC, Krishnan KR et al. Association of AGTR1 with 18-month treatment outcome in late-life depression. Am J Geriatr Psychiatry 2007; 15:564-72.

Kondo S, Chatuphonprasert W, Jaruchotikamol A, Sakuma T, Nemoto N. Cellular glutathione content modulates the effect of andrographolide on β-naphthoflavone-induced CYP1A1 mRNA expression in mouse hepatocytes. Toxicology 2011; 280:18-23.

Kondo T, Tanaka O, Otani K et al. Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug. Psychopharmacology 1996; 127:311-4.

Kondoh N, Wakatsuki T, Ryo A et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999; 59:4990-6.

Kondratyuk TP, Park EJ, Marler LE et al. Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol Nutr Food Res 2011; 55:1249-65.

Konecny GE, Thomssen C, Lück HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 96:1141-51.

Kong B, Guo GL. Enhanced in vitro refolding of fibroblast growth factor 15 with the assistance of SUMO fusion partner. PLoS One 2011. doi:10. 1371/journal. pone. 0020307.

Kong QL, Hu LJ, Cao JY et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 2010. doi:10. 1371/journal. ppat. 1000940.

Kong WM, Chik Z, Ramachandra M, Subramaniam U, Aziddin RE, Mohamed Z. Evaluation of the effects of Mitragyna speciosa alkaloid extract on cytochrome P450 enzymes using a high throughput assay. Molecules 2011; 16:7344-56.

König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010; 65:2319-28.

Konishi H, Tanaka K, Minouchi T, Yamaji A. Urinary 6beta-hydroxycortisol/17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme induction. Ann Clin Biochem 2004; 41:335-7.

Konishi I, Horiike N, Hiasa Y, Michitaka K, Onji M. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology 2004; 47:114-20.

Konishi M, Ishii H. Role of microsomal enzymes in development of alcoholic liver diseases. J Gastroenterol Hepatol 2007; 22 Suppl 1:7-10.

Konkle AT, McCarthy MM. Developmental time course of estradiol, testosterone, and dihydrotestosterone levels in discrete regions of male and female rat brain. Endocrinology 2011; 152:223-35.

Kono T, Moto M, Muguruma M et al. Enhancement of hepatocellular proliferative activity of kojic acid in mice by a simultaneous administration of ascorbic acid. J Vet Med Sci 2007; 69:899-908.

Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci USA 1985; 82:1810-4.

Konstantinovsky S, Smith Y, Zilber S et al. Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol 2010. doi:10. 1155/2010/969084.

Konsue N, Ioannides C. Modulation of carcinogen-metabolising cytochromes P450 in human liver by the chemopreventive phytochemical phenethyl isothiocyanate, a constituent of cruciferous vegetables. Toxicology 2010; 268:184-90.

Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf 2010; 9:633-41.

Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 2010; 12:639-57.

Kooij G, Backer R, Koning JJ et al. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 2009. doi:10. 1371/journal. pone. 0008212.

Kooij G, Mizee MR, van Horssen J et al. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain 2011; 134:555-70.

Kool M, de Haas M, Scheffer GL et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57:3537-47.

Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 2010; 69:465-74.

Koolen SL, van Waterschoot RA, van Tellingen O et al. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies. J Clin Pharmacol 2011. doi:10. 1177/0091270010397051.

Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn’s disease. Drug Discov Today 2007; 12:125-31.

Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010; 11:163-75.

Kopecka J, Campia I, Brusa D et al. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med 2011; 15:1492-504.

Kopf D, Cheng LS, Blandau P et al. Association of insulin sensitivity and glucose tolerance with the c. 825C>T variant of the G protein beta-3 subunit gene. J Diabetes Complications 2008; 22:205-9.

Korashy HM, El-Kadi AO. The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab Rev 2006; 38:411-50.

Koren A, Levin C, Dgany O et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol 2008; 83:366-70.

Korhonen S, Romppanen EL, Hiltunen M et al. Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are associated with polycystic ovary syndrome. Fertil Steril 2003; 79:1353-7.

Korhonen T, Tolonen A, Uusitalo J, Lundgren S, Jalonen J, Laine K. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol 2005; 60:69-75.

Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol 2008; 110:56-66.

Korjamo T, Honkakoski P, Toppinen MR et al. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci 2005; 26:266-79.

Korjamo T, Mönkkönen J, Uusitalo J, Turpeinen M, Pelkonen O, Honkakoski P. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm Res 2006; 23:1991-2001.

Kornhuber J, Weigmann H, Röhrich J et al. Region specific distribution of levomepromazine in the human brain. J Neural Transm 2006; 113:387-97.

Korotkina RN, Matskevich GN, Devlikanova ASh, Vishnevskii AA, Kunitsyn AG, Karelin AA. Activity of glutathione-metabolizing and antioxidant enzymes in malignant and benign tumors of human lungs. Bull Exp Biol Med 2002; 133:606-8.

Koryakina A, Aeberhard J, Kiefer S, Hamburger M, Küenzi P. Regulation of secretases by all-trans-retinoic acid. FEBS J 2009; 276:2645-55.

Korynevska A, Heffeter P, Matselyukh B et al. Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochem Pharmacol 2007; 74:1713-26.

Korytina GF, Akhmadishina LZ, Viktorova TV. The CYP1B1 and CYP2F1 genes polymorphisms frequency in three ethnic groups of Bashkortostan and chronic obstructive pulmonary disease patients. Mol Biol 2010; 44:33-41.

Korzekwa KR, Krishnamachary N, Shou M et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37:4137-47.

Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004; 26:530-4.

Kosel M, Wild W, Bell A et al. Eicosanoid formation by a cytochrome P450 isoform expressed in the pharynx of Caenorhabditis elegans. Biochem J 2011; 435:689-700.

Koshiol J, Hildesheim A, Gonzalez P et al. Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. Cancer Epidemiol Biomarkers Prev 2009; 18:1631-7.

Kosina P, Maurel P, Ulrichová J, Dvorák Z. Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2005; 19:149-53.

Koski A, Ojanperä I, Sistonen J, Vuori E, Sajantila A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol 2007; 28:259-61.

Koski A, Sistonen J, Ojanperä I, Gergov M, Vuori E, Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci Int 2006; 158:177-83.

Kossugue PM, Paim JF, Navarro MM et al. Central core disease due to recessive mutations in RYR1 gene: is it more common than described? Muscle Nerve 2007; 35:670-4.

Kostic TS, Stojkov NJ, Bjelic MM, Mihajlovic AI, Janjic MM, Andric SA. Pharmacological doses of testosterone upregulated androgen receptor and 3-Beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase and impaired leydig cells steroidogenesis in adult rats. Toxicol Sci 2011; 121:397-407.

Kostrikis LG, Neumann AU, Thomson B et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999; 73:10264-71.

Kostrubsky VE, Lewis LD, Strom SC et al. Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 1998; 355:131-6.

Kostulas N, Markaki I, Kostulas V, Hillert J, Kostulas K. Common CCR 5 polymorphism in stroke: the CCR 5 delta32 polymorphism differentiates cardioembolism from other aetiologies of ischaemic cerebrovascular diseases. Scand J Immunol 2009; 70:475-80.

Kosuge K, Chuang AI, Uematsu S et al. Discovery of osmosensitive transcriptional regulation of human cytochrome P450 3As by the tonicity-responsive enhancer binding protein (nuclear factor of activated T cells 5). Mol Pharmacol 2007; 72:826-37.

Kosuge K, Jun Y, Watanabe H et al. Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos 2001; 29:1284-9.

Kosuge K, Nishimoto M, Kimura M, Umemura K, Nakashima M, Ohashi K. Enhanced effect of triazolam with diltiazem. Br J Clin Pharmacol 1997; 43:367-72.

Kosugi S, Inoue S, Matsuda A, Jhiang SM. Novel, missense and loss-of-function mutations in the sodium/iodide symporter gene causing iodide transport defect in three Japanese patients. J Clin Endocrinol Metab 1998; 83:3373-6.

Koszalka GW, Johnson NW, Good SS et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2002; 46:2373-80.

Kot M, Daniel WA. Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep 2007; 59:296-305.

Kot M, Daniel WA. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep 2008; 60:789-97.

Kot M, Daniel WA. The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450s including CYP2C isoforms. Biochem Pharmacol 2008; 76:543-51.

Kot M, Daniel WA. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacol Rep 2009; 61:1216-20.

Kota BP, Abdul MI, Allen JD, Kalagara M, Roufogalis BD. Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin- a pilot study. Fundam Clin Pharmacol 2011. doi:10. 1111/j. 1472-8206. 2011. 00944. x.

Kota BP, Allen JD, Roufogalis BD. The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Basic Clin Pharmacol Toxicol 2011; 109:97-102.

Kota BP, Tran VH, Allen J, Bebawy M, Roufogalis BD. Characterization of PXR mediated P-glycoprotein regulation in intestinal LS174T cells. Pharmacol Res 2010; 62:426-31.

Kotaka T, Ujike H, Morita Y et al. Association study between casein kinase 1 epsilon gene and methamphetamine dependence. Ann NY Acad Sci 2008; 1139:43-8.

Kotani Y, Nishimura Y, Maeda H, Yokoyama M. Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma 1999; 36:583-90.

Kotka M, Lieden A, Pettersson S, Trinchieri V, Masci A, D’Amato M. Solute carriers (SLC) in inflammatory bowel disease: a potential target of probiotics? J Clin Gastroenterol 2008; 42:133-5.

Kotlyar M, Brauer LH, Tracy TS et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005; 25:226-9.

Kotlyar M, Brewer ER, Golding M, Carson SW. Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. J Clin Psychopharmacol 2003; 23:652-6.

Kotrbová V, Mrázová B, Moserová M et al. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. Biochem Pharmacol 2011; 82:669-80.

Kotrikadze N, Alibegashvili M, Zibzibadze M et al. Activity and content of antioxidant enzymes in prostate tumors. Exp Oncol 2008; 30:244-7.

Kotsovolou O, Ingelman-Sundberg M, Lang MA et al. Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1075-84.

Kotsuma M, Hanzawa H, Iwata Y, Takahashi K, Tokui T. Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos 2008; 36:1938-43.

Kotsuma M, Tokui T, Freudenthaler S, Nishimura K. Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans. Drug Metab Dispos 2008; 36:1505-11.

Kotsuma M, Tokui T, Ishizuka-Ozeki T et al. CYP2D6-Mediated metabolism of a novel acyl coenzyme A: cholesterol acyltransferase inhibitor, pactimibe, and its unique plasma metabolite, R-125528. Drug Metab Dispos 2008; 36:529-34.

Kotta CM, Anastasakis A, Gatzoulis K, Papagiannis J, Geleris P, Stefanadis C. Cardiac ion channel gene mutations in Greek long QT syndrome patients. J Appl Genet 2010; 51:515-8.

Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98:1752-9.

Koudriakova T, Iatsimirskaia E, Utkin I et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26:552-61.

Koue T, Kubo M, Funaki T et al. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. Biol Pharm Bull 2007; 30:2154-8.

Kouhi H, Hamzeiy H, Barar J, Asadi M, Omidi Y. Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Genet Test Mol Biomarkers 2009; 13:665-70.

Koukouritaki SB, Hines RN. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics 2005; 6:807-22.

Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol 2005; 28:472-3.

Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982; 42:5030-7.

Kousalová L, Anzenbacherová E, Baranová J, Anzenbacher P, Skoumalová I, Vondraková J. Presence of cytochrome P450 enzymes in human CD34+ haematopoietic progenitor cells. Gen Physiol Biophys 2004; 23:251-7.

Kousba A, Soll R, Yee S, Martin M. Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase. Drug Metab Dispos 2007; 35:2242-51.

Kousta E, Papathanasiou A, Skordis N. Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals. Hormones 2010; 9:218-131.

Koutros S, Berndt SI, Sinha R et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res 2009; 69:1877-84.

Kovac MK, Rakicevic LB, Radojkovic DP. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC. -1639 A/A and CYP2C9*1/*3 genotypes. J Thromb Thrombolysis 2011; 32:368-71.

Kovacs DM, Fausett HJ, Page KJ et al. Alzheimer’s-associated presenilins 1 and 2 : neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 1996; 2:224-9.

Kovacs DM, Mancini R, Henderson J et al. Staurosporine-induced activation of caspase-3 is potentiated by presenilin 1 familial Alzheimer’s disease mutations in human neuroglioma cells. J Neurochem 1999; 73:2278-85.

Kovacs GG, Molnár K, László L et al. A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol 2011; 122:205-22.

Kovaleva IE, Krynetskii EY, Luzikov VN. Transgenic yeast expressing human cytochrome P450s can serve as a tool in studies of the mechanisms of their induction by various effectors. Biochem Biophys Res Commun 1996; 221:129-32.

Kovár J, Lenícek M, Zimolová M, Vítek L, Jirsa M, Pitha J. Regulation of diurnal variation of cholesterol 7alpha-hydroxylase (CYP7A1) activity in healthy subjects. Physiol Res 2010; 59:233-8.

Kovarik JM, Bartlett M, Rordorf C et al. Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. Int J Clin Pharmacol Ther 2010; 48:103-8.

Kovarik JM, Dole K, Riviere GJ et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J Clin Pharmacol 2009; 49:212-8.

Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002; 36:981-5.

Kovarik JM, Huang HL, Slade A, Sfikas N, Chandler PA. The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. Br J Clin Pharmacol 2009; 68:381-5.

Kovtun I, Therneau T, McMurray C. Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington’s disease gene. Hum Molec Genet 2000; 9:2767-75.

Kovtun YV, Audette CA, Mayo MF et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010; 70:2528-37.

Kowalska A, Jamrozik Z, Kwiecinski H. Progressive supranuclear palsy-parkinsonian disorder with tau pathology. Folia Neuropathol 2004; 42:119-23.

Kowarski AA, Schneider J, Ben-Galim E, Weldon VV, Daughaday WH. Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH. J Clin Endocrinol Metab 1978; 47:461-4.

Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278:21-30.

Koyama E, Chiba K, Tani M, Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997; 281:1199-210.

Koyama E, Tanaka T, Chiba K et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4’-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996; 16:286-93.

Koyama H, Iesato A, Fukushima Y et al. A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer. Gan To Kagaku Ryoho 2011; 38:1123-6.

Koyama N, Sasabe H, Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica 2002; 32:573-86.

Koyama N, Yasui M, Oda Y et al. Genotoxicity of acrylamide in vitro: Acrylamide is not metabolically activated in standard in vitro systems. Environ Mol Mutagen 2011; 52:11-9.

Koyano S, Kurose K, Saito Y et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 2004; 32:149-54.

Koyano S, Saito Y, Sai K et al. Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population. Drug Metab Pharmacokinet 2005; 20:79-84.

Kozawa M, Honma M, Suzuki H. Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab Dispos 2009; 37:1234-41.

Kozłowska-Rup D, Czekaj P. Barrier role of ABC family of proteins in human placenta. Ginekol Pol 2011; 82:56-63.

Kozlowski KS, Celermajer JM, Tink AR. Humero-spinal dysostosis with congenital heart disease. Am J Dis Child 1974; 127:407-10.

Kraemer T, Pflugmann T, Bossmann M et al. Fenproporex N-dealkylation to amphetamine-enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochem Pharmacol 2004; 68:947-57.

Kraft P, Pharoah P, Chanock SJ et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 2005. doi:10. 1371/journal. pgen. 0010068.

Kragelund C, Hansen C, Torpet LA et al. Expression of two drug-metabolizing cytochrome P450-enzymes in human salivary glands. Oral Dis 2008; 14:533-40.

Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359:1033-4.

Krajinovic M, Robaey P, Chiasson S et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 2005; 6:293-302.

Kramer MA, Rettie AE, Rieder MJ, Cabacungan ET, Hines RN. Novel CYP2C9 promoter variants and assessment of their impact on gene expression. Mol Pharmacol 2008; 73:1751-60.

Kramer RE, Ho IK. Pharmacokinetics and pharmacodynamics of methyl parathion. Zhonghua Yi Xue Za Zhi 2002; 65:187-99.

Kranendonk M, Carreira F, Theisen P, et al. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. Mutat Res 1999; 441:73-83.

Kranzhofer R, Ruef J. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets 2006; 17:163-9.

Krasznai M, Szaniszlo K, Kraxner H et al. Association of TLR-4 and TNF-alpha polymorphisms with clinical symptoms and cytokine levels in patients with allergic rhinitis. Eur Arch Otorhinolaryngol 2011; 268 :561-7.

Krasznai ZT, Tóth A, Mikecz P et al. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG. Eur J Pharm Sci 2010; 41:665-9.

Kraugerud M, Zimmer KE, Dahl E et al. Three structurally different polychlorinated biphenyl congeners (Pcb 118, 153, and 126) affect hormone production and gene expression in the human H295R in vitro model. J Toxicol Environ Health A 2010; 73:1122-32.

Kraugerud M, Zimmer KE, Ropstad E, Verhaegen S. Perfluorinated compounds differentially affect steroidogenesis and viability in the human adrenocortical carcinoma (H295R) in vitro cell assay. Toxicol Lett 2011; 205:62-8.

Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is a ssociated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008; 117:1537-44.

Kravchenko LV, Trusov NV, Aksenov IV et al. Effects of green tea extract and its components on antioxidant status and activities of xenobiotic metabolizing enzymes of rats. Vopr Pitan 2011; 80:9-15.

Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24:695-708.

Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999; 66:40-50.

Krechowec S, Plagge A. Physiological dysfunctions associated with mutations of the imprinted Gnas locus. Physiology 2008; 23:221-9.

Krege JH, John SW, Langenbach LL et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995; 375:146-8.

Kreil S, Waghorn K, Ernst T et al. A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 2010; 95:148-52.

Kreisl WC, Liow JS, Kimura N et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 2010; 51:559-66.

Kremer EJ, Pritchard M, Lynch M et al. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 1991; 252:1711-4.

Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs. Biochem Pharmacol 2000; 59:1563-71.

Kretowski A, McFann K, Hokanson JE et al. Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosis. Diabetes 2007; 56:863-71.

Kretowski A, Wawrusiewicz N, Mironczuk K, Mysliwiec J, Kretowska M, Kinalska I. Intercellular adhesion molecule 1 gene polymorphisms in Graves’ disease. J Clin Endocrinol Metab 2003; 88:4945-9.

Kretschmer M, Leroch M, Mosbach A et al. Fungicide-driven evolution and molecular basis of multidrug resistance in field populations of the grey mould fungus Botrytis cinerea. PLoS Pathog 2009. doi:10. 1371/journal. ppat. 1000696.

Kretzschmar HA, Neumann M, Stavrou D. Codon 178 mutation of the human prion gene in a German family (Backer family): sequencing data from 72-year-old celloidin-embedded brain tissue. Acta Neuropath 1995; 89:96-8.

Kriegl JM, Arnhold T, Beck B, Fox T. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. J Comput Aided Mol Des 2005; 19:189-201.

Kriegl JM, Eriksson L, Arnhold T, Beck B, Johansson E, Fox T. Multivariate modeling of cytochrome P450 3A4 inhibition. Eur J Pharm Sci 2005; 24:451-63.

Krikova EV, Val’dman EA, Avakian GN et al. Association study of the SCN1 gene polymorphism and effective dose of lamotrigine. Zh Nevrol Psikhiatr Im S S Korsakova 2009; 109:57-62.

Kringen MK, Haug KB, Grimholt RM et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol 2011. doi:10. 1155/2011/739751.

Krippendorff BF, Neuhaus R, Lienau P, Reichel A, Huisinga W. Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values. J Biomol Screen 2009; 14:913-23.

Krishna G, Moton A, Ma L et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009; 31:286-98.

Krishna R, Bergman A, Larson P et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 2007; 47:165-74.

Krishnakumar D, Gurusamy U, Dhandapani K et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam Clin Pharmacol 2011. doi:10. 1111/j. 1472-8206. 2010. 00917. x.

Krishnamoorthy N, Gajendrarao P, Thangapandian S, Lee Y, Lee KW. Probing possible egress channels for multiple ligands in human CYP3A4: A molecular modeling study. J Mol Model 2010; 16:607-14

Krishnamurthy P, Schuetz JD. The Role of ABCG2 and ABCB6 in porphyrin metabolism and cell survival. Curr Pharm Biotechnol 2011; 12:647-55.

Krishnamurthy P, Schwab M, Takenaka K et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 2008; 68:4983-9.

Krishnamurthy RK, Johnson GH. Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model. J Biol Chem 2004; 279:7893-900.

Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007; 35:180-4.

Krishnaswamy S, Hao Q, Al-Rohaimi A et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5’-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther 2005; 313:1331-9.

Krishnaswamy S, Hao Q, Al-Rohaimi A et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther 2005; 313:1340-6.

Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000; 462:323-33.

Kristensen VN, Kure EH, Erikstein B, Harada N, Børresen-Dale A. Genetic susceptibility and environmental estrogen-like compounds. Mutat Res 2001; 482:77-82.

Kristiansen MT, Clausen LR, Nielsen S et al. Expression of leptin receptor isoforms and effects of leptin on the proliferation and hormonal secretion in human pituitary adenomas. Horm Res 2004; 62:129-36.

Kristiansen OP, Nolsøe RL, Larsen L et al. Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. Hum Mol Genet 2003; 12:1101-10.

Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998; 92:2382-8.

Krivoruk Y, Kinirons MT, Wood AJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994; 56:608-14.

Krivoy A, Fischel T, Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur Neuropsychopharmacol 2008; 18:395-405.

Kroese M, Zimmern RL, Pinder SE. HER2 status in breast cancer-an example of pharmacogenetic testing. J R Soc Med 2007; 100:326-9.

Kroetz DL, Pauli-Magnus C, Hodges LM et al. Pharmacogenetics of membrane transporters investigators. sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-94.

Kroetz DL, Xu F. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 2005; 45:413-38.

Krohmer RW, Boyle MH, Lutterschmidt DI, Mason RT. Seasonal aromatase activity in the brain of the male red-sided garter snake. Horm Behav 2010; 58:485-92.

Kroiss S, Albisetti M. Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency. Biologics 2010; 4:51-60.

Król M, Pawłowski KM, Skierski J et al. Transcriptomic “portraits” of canine mammary cancer cell lines with various phenotypes. J Appl Genet 2010; 51:169-83.

Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A. Investigation of sarizotan’s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol 2006; 62:277-84.

Krstić D, Colović M, Krinulović K, Djurić D, Vasić V. Inhibition of AChE by single and simultaneous exposure to malathion and its degradation products. Gen Physiol Biophys 2007; 26:247-53.

Krstić DZ, Colović M, Kralj MB et al. Inhibition of AChE by malathion and some structurally similar compounds. J Enzyme Inhib Med Chem 2008; 23:562-73.

Kruber P, Trump S, Behrens J, Lehmann I. T-2 toxin is a cytochrome P450 1A1 inducer and leads to MAPK/p38- but not aryl hydrocarbon receptor-dependent interleukin-8 secretion in the human intestinal epithelial cell line Caco-2. Toxicology 2011; 284:34-41.

Krueger SK, Siddens LK, Henderson MC et al. Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics. Pharmacogenet Genomics 2005; 15:245-56.

Krueger SK, Siddens LK, Martin SR et al. Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent. Drug Metab Dispos 2004; 32:1337-40.

Krueger SK, Vandyke JE, Williams DE, Hines RN. The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug Metab Rev 2006; 38:139-47.

Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005; 106:357-87.

Krug M, Voigt B, Baumert C, Lüpken R, Molnár J, Hilgeroth A. First biological evaluation of developed 3-benzyloxyfluorenes as novel class of MDR modulators. Eur J Med Chem 2010; 45:2683-8.

Kruglova IS, Meshchaninova MI, Venyaminova AG, Zenkova MA, Vlasov VV, Chernolovskaia EL. Cholesterol-modified anti-MDR1 small interfering RNA: Uptake and biological activity. Mol Biol 2010; 44:284-93.

Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010; 21:178-85.

Krupoves A, Mack D, Seidman E, Deslandres C, Amre D. Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with crohn’s disease. Inflamm Bowel Dis 2011; 17:2308-17.

Krupoves A, Seidman EG, Mack D et al. Associations between ABCB1/MDR1 gene polymorphisms and Crohn’s disease: a gene-wide study in a pediatric population. Inflamm Bowel Dis 2009; 15:900-8.

Krusekopf S, Roots I, Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 2003; 466:7-12.

Krusekopf S, Roots I. St. John’s wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharmacogenet Genomics 2005; 15:817-29.

Kruszyna Ł, Lianeri M, Roszak A, Jagodziński PP. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. Clin Biochem 2010; 43:545-8.

Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92:949-53.

Krynetskiy E, McDonnell P. Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther 2007; 322:427-34.

Krzywkowski K, Davies PA, Feinberg-Zadek PL, Bräuner-Osborne H, Jensen AA. High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci USA 2008; 105:722-7.

Krzywkowski K, Davies PA, Irving AJ, Bräuner-Osborne H, Jensen AA. Characterization of the effects of four HTR3B polymorphisms on human 5-HT3AB receptor expression and signalling. Pharmacogenet Genomics 2008; 18:1027-40.

Ku CS, Pawitan Y, Sim X et al. Genomic copy number variations in three Southeast Asian populations. Hum Mutat 2010; 31:851-7.

Ku GY, Ilson DH, Schwartz LH et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2008; 62:875-80.

Ku HY, Ahn HJ, Seo KA et al. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 2008; 36:986-90.

Ku TK, Crowe DL. Genomic profiling of decreased DNA damage response in human squamous carcinoma cells. Mol Med Report 2008; 1:105-17.

Kuai XY, Ji ZY, Zhang HJ. Mitochondrial uncoupling protein 2 expression in colon cancer and its clinical significance. World J Gastroenterol 2010; 16:5773-8.

Kuang YH, Shen T, Chen X et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010; 79:154-61.

Kuba K, Imai Y, Rao S et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875-9.

Küblbeck J, Reinisalo M, Mustonen R, Honkakoski P. Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors. Eur J Pharm Sci 2010; 40:263-72.

Kubo M, Koue T, Inaba A et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20:55-64.

Kubo M, Koue T, Maune H, Fukuda T, Azuma J. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007; 22:358-66.

Kubota A, Stegeman JJ, Goldstone JV et al. Cytochrome P450 CYP2 genes in the common cormorant: Evolutionary relationships with 130 diapsid CYP2 clan sequences and chemical effects on their expression. Comp Biochem Physiol C Toxicol Pharmacol 2011; 153:280-9.

Kubota M, Shimmura S, Miyashita H, Kawashima M, Kawakita T, Tsubota K. The anti-oxidative role of ABCG2 in corneal epithelial cells. Invest Ophthalmol Vis Sci 2010; 51:5617-22.

Kubota T, Hibi N, Chiba K. Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population. Biochem Pharmacol 1998; 55:2039-42.

Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000; 50:31-4.

Kuca K, Juna D, Musilek K. Structural requirements of acetylcholinesterase reactivators. Mini Rev Med Chem 2006; 6:269-77.

Kucukali CI, Aydin M, Ozkok E et al. Do schizophrenia and bipolar disorders share a common disease susceptibility variant at the MMP3 gene? Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:557-61.

Küçükkilinç T, Cochran R, Kalisiak J et al. Investigating the structural influence of surface mutations on acetylcholinesterase inhibition by organophosphorus compounds and oxime reactivation. Chem Biol Interact 2010; 187:238-40.

Kucherlapati MH, Lee K, Nguyen AA et al. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 2010; 138:993-1002.

Kucherlapati MH, Yang K, Fan K et al. Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. Proc Natl Acad Sci USA 2008; 105:15493-8.

Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37:435-56.

Kudo S, Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 1998; 54:253-9.

Kudo S, Okumura H, Miyamoto G, Ishizaki T. Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine. Drug Metab Dispos 1999; 27:303-8.

Kudo S, Uchida M, Odomi M. Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol 1997; 52:479-85.

Kudo T, Kawashima M, Tamagawa T, Shibata S. Clock mutation facilitates accumulation of cholesterol in the liver of mice fed a cholesterol and/or cholic acid diet. Am J Physiol Endocrinol Metab 2008; 294:120-30.

Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009; 10:124.

Kudzi W, Dodoo AN, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010; 11:111.

Kuehl GE, Bigler J, Potter JD, Lampe JW. Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos 2006; 34:199-202.

Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33:1027-35.

Kuhlenbaeumer G, Huge A, Berger K et al. Genetic variants in the C-reactive protein gene are associated with microangiopathic ischemic stroke. Cerebrovasc Dis 2010; 30:476-82.

Kuhn JG. Pharmacology of irinotecan. Oncology 1998; 12:39-42.

Kuhn JG, Chang SM, Wen PY et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007; 13:7401-6.

Kuhn PH, Wang H, Dislich B et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010; 29:3020-32.

Kuhn UD, Kirsch M, Merkel U et al. Reboxetine and cytochrome P450-comparison with paroxetine treatment in humans. Int J Clin Pharmacol Ther 2007; 45:36-46.

Kühne A, Sezer O, Heider U et al. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther 2008; 83:749-57.

Kühnle M, Egger M, Müller C et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009; 52:1190-7.

Kuipers I, Li J, Vreeswijk-Baudoin I et al. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail 2010; 12:1042-50.

Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Eng J Med 1998; 338:86-93.

KuKanich B, Hubin M. The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. J Vet Pharmacol Ther 2010; 33:42-9.

Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem 2008; 8:47-53.

Kukar T, Prescott S, Eriksen JL et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007; 8:54.

Kukreti R, Bhatnagar P, B-Rao C et al. Beta(2)-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics*. Pharmacogenomics 2005; 6:399-410.

Kukull WA, Larson EB, Bowen JD et al. Solvent exposure as a risk factor for Alzheimer’s disease: a case-control study. Am J Epidemiol 1995; 141:1059-71

Kulemann V, Bauer M, Graninger W, Joukhadar C. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology 2005; 75:165-78.

Kulkarni H, Agan BK, Marconi VC et al. CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals. PLoS One 2008. doi:10. 1371/journal. pone. 0003165.

Kulminski AM, Culminskaya I, Ukraintseva SV et al. Trade-off in the effects of the apolipoprotein E polymorphism on the ages at onset of CVD and cancer influences human lifespan. Aging Cell 2011; 10:533-41.

Kulminski AM, Culminskaya I, Ukraintseva SV, Arbeev KG, Land KC, Yashin AI. Beta2-adrenergic receptor gene polymorphisms as systemic determinants of healthy aging in an evolutionary context. Mech Ageing Dev 2010; 131:338-45.

Kulminski AM, Culminskaya IV, Ukraintseva SV et al. Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: the case of myocardial infarction. Rejuvenation Res 2010; 13:13-21.

Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126:322-42.

Kumar A, Ahmad I, Shukla S et al. Effect of zinc and paraquat co-exposure on neurodegeneration: Modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats. Free Radic Res 2010; 44:950-65.

Kumar A, Li Y, Patil S, Jain S. A haplotype of the angiotensinogen gene is associated with hypertension in african americans. Clin Exp Pharmacol Physiol 2005; 32:495-502.

Kumar A, Remmel RP, Mann HJ, Beilman GJ. Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model. J Surg Res 2011; 167:231-43.

Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26:3128-37.

Kumar GN, Dykstra J, Roberts EM et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999; 27:902-8.

Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277:423-31.

Kumar J, Das SK, Sharma P, Karthikeyan G, Ramakrishnan L, Sengupta S. Homocysteine levels are associated with MTHFR A1298C polymorphism in Indian population. J Hum Genet 2005; 50:655-63.

Kumar P, Mendelson CR. Estrogen-related receptor {gamma} (ERR{gamma}) mediates oxygen-dependent induction of aromatase (CYP19) gene expression during human trophoblast differentiation. Mol Endocrinol 2011; 25:1513-26.

Kumar R, Nejatizadeh A, Arif E et al. Multi-locus interactions of vascular homeostasis genes in essential hypertension: a gender-based study. Clin Chim Acta 2009; 405:87-93.

Kumar S, Davydov DR, Halpert JR. Role of cytochrome B5 in modulating peroxide-supported cyp3a4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity. Drug Metab Dispos 2005; 33:1131-6.

Kumar S, Liu H, Halpert JR. Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos 2006; 34:1958-65.

Kumar S, Qiu H, Oezguen N, Herlyn H, Halpert JR, Wojnowski L. Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection. Drug Metab Dispos 2009; 37:1328-33.

Kumar S, Tan EY, Hartmann G et al. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos 2010; 38:474-83.

Kumar V, Khosla R, Gupta V, Sarin BC, Sehajpal PK. Differential association of tumour necrosis factor-alpha single nucleotide polymorphism (-308) with tuberculosis and bronchial asthma. Natl Med J India 2008; 21:120-2.

Kumar V, Schuck EL, Pelletier RD et al. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1687-8.

Kumar V, Singh S, Ahmed RS, Banerjee BD, Ahmed T, Pasha ST. Frequency of common CYP1B1 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol 2009; 28:392-6.

Kumarakulasingham M, Rooney PH, Dundas SR et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 2005; 11:3758-65.

Kumaran A, Kapoor RR, Flanagan SE, Ellard S, Hussain K. Congenital hyperinsulinism due to a compound heterozygous ABCC8 mutation with spontaneous resolution at eight weeks. Horm Res Paediatr 2010; 73:287-92.

Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK, Mittal B. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet 2011; 17 Suppl 1:32-40.

Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2011; 67:63-71.

Kümmerle T, Lehmann C, Hartmann P, Wyen C, Fätkenheuer G. Vicriviroc: a CR5 antagonist for treatment-experienced patients with HIV-1 infection. Expert Opin Investig Drugs 2009; 18:1773-85.

Kümpfel T, Hoffmann LA, Pellkofer H et al. Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. Neurology 2008; 71:1812-20.

Kumpulainen H, Mähönen N, Laitinen ML et al. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure. J Med Chem 2006; 49:1207-11.

Kumsta R, Moser D, Streit F, Koper JW, Meyer J, Wüst S. Characterization of a glucocorticoid receptor gene (GR, NR3C1) promoter polymorphism reveals functionality and extends a haplotype with putative clinical relevance. Am J Med Genet B Neuropsychiatr Genet 2009; 150:476-82.

Kundu R, Dasgupta S, Biswas A et al. Carlinoside reduces hepatic bilirubin accumulation by stimulating bilirubin-UGT activity through Nrf2 gene expression. Biochem Pharmacol 2011; 82:1186-97.

Kung MH, Yukata K, O’Keefe RJ, Zuscik MJ. Aryl hydrocarbon receptor-mediated impairment of chondrogenesis and fracture healing by cigarette smoke and benzo(a)pyrene. J Cell Physiol 2011. doi:10. 1002/jcp. 22819.

Kung WJ, Lin CC, Liu SH, Chaung HC. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technol Ther 2010; 12:809-13.

Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997; 89:1939-43.

Kunicki TJ, Nugent DJ. The influence of platelet glycoprotein polymorphisms on receptor function and risk for thrombosis. Vox Sang 2002; 83 Suppl 1:85-90.

Kunicki TJ, Williams SA, Salomon Dr et al. Genetics of platelet reactivity in normal, healthy individuals. J Thromb Haemost 2009; 7:2116-22.

Kunii T, Fukasawa T, Yasui-Furukori N et al. Interaction study between enoxacin and fluvoxamine. Ther Drug Monit 2005; 27:349-53.

Kunikata T, Yamane H, Segi E et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immun 2005; 6:524-31.

Kuntner C, Bankstahl JP, Bankstahl M et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging 2010; 37:942-53.

Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 2006; 34:583-90.

Kuo BP, Hu OY, Hsiong CH, Pao LH, Chen TS, Hung CF. Single-point plasma or urine dextromethorphan method for determining CYP3A activity. Biopharm Drug Dispos 2003; 24:367-73.

Kuo TC, Chiang PC, Yu CC et al. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways. Biochem Pharmacol 2011; 81:1136-44.

Kuperman AV, Kalgutkar AS, Marfat A, Chambers RJ, Liston TE. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue. Drug Metab Dispos 2001; 29:1403-9.

Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krähenbühl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45:355-9.

Kuppens IE, Breedveld P, Beijnen JH, Schellens JH. Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 2005; 23:443-64.

Kurata N, Nishimura Y, Iwase M et al. Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica 1998; 28:1041-7.

Kurbanova D, Eliseyeva M. Genetic background of left ventricular hypertrophy in Uzbek hypertensive men. Turk Kardiyol Dern Ars 2010; 38:466-72.

Kurian MA, Zhen J, Cheng SY et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 2009; 119:1595-603.

Kuribayashi S, Goto K, Naito S, Kamataki T, Yamazaki H. Human cytochrome P450 1A2 involvement in the formation of reactive metabolites from a species-specific hepatotoxic pyrazolopyrimidine derivative, 5-n-butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine. Chem Res Toxicol 2009; 22:323-31.

Kuriya S, Ohmori S, Hino M et al. Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes. Drug Metab Dispos 2000; 28:73-8.

Kuriyama S, Shimazu T, Hozawa A et al. No effect of the Trp64Arg variant of the beta3-adrenergic receptor gene on weight loss by diet and exercise intervention among Japanese adults. Metabolism 2008; 57:1570-5.

Kurland L, Hallberg P, Melhus H et al. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Am J Hypertens 2008; 21:836-9.

Kurland L, Liljedahl U, Karlsson J et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17:8-13.

Kurland L, Melhus H, Karlsson J et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20:657-63.

Kurnik D, Cunningham AJ, Sofowora GG et al. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics 2009; 10:1581-7.

Kurnik D, Friedman EA, Muszkat M et al. Genetic variants in the alpha2C-adrenoceptor and G-protein contribute to ethnic differences in cardiovascular stress responses. Pharmacogenet Genomics 2008; 18:743-50.

Kurnik D, Li C, Sofowora GG et al. Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics 2008; 18:895-902.

Kurnik D, Muszkat M, Friedman EA et al. Effect of the alpha2C-adrenoreceptor deletion322-325 variant on sympathetic activity and cardiovascular measures in healthy subjects. J Hypertens 2007; 25:763-71.

Kurnik D, Muszkat M, Li C et al. Variations in the alpha2A-adrenergic receptor gene and their functional effects. Clin Pharmacol Ther 2006; 79:173-85.

Kuroda J, Yamamoto M, Nagoshi H et al. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 2010; 8:994-1001.

Kurokawa N, Nakai K, Kameo S, Liu ZM, Satoh H. Association of BMI with the beta3-adrenergic receptor gene polymorphism in Japanese: meta-analysis. Obes Res 2001; 9:741-5.

Kurokawa N, Young EH, Oka Y et al. The ADRB3 Trp64Arg variant and BMI: a meta-analysis of 44 833 individuals. Int J Obes 2008; 32:1240-9.

Kurokohchi K, Yoneyama H, Nishioka M, Ichikawa Y. Inhibitory effect of rifampicin on the depressive action of interleukin-1 on cytochrome P-450-linked monooxygenase system. Metabolism 2001; 50:231-6.

Kurose K, Koyano S, Ikeda S, Tohkin M, Hasegawa R, Sawada J. 5’ diversity of human hepatic PXR (NR1I2) transcripts and identification of the major transcription initiation site. Mol Cell Biochem 2005; 273:79-85.

Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997; 62:145-56.

Kurtz JE, Asmane I, Voegeli AC et al. A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis. Sarcoma 2010; 2010:458156.

Kurz A, Egensperger R, Lautenschlager N, Romero B, Graeber MB, Muller U. Apolipoprotein E epsilon-4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer’s disease. Neurology 1996; 47:440-3.

Kurzawski M, Dziewanowski K, Lener A, Drozdzik M. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol 2009; 65:533-40.

Kurzrock R, Shtalrid M, Romero P et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 1987; 325:631-5.

Kusama M, Kubota T, Matsukura Y et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta 2006; 368:93-8.

Kusama M, Toshimoto K, Maeda K et al. In silico classification of major clearance pathways of drugs with their physiochemical parameters. Drug Metab Dispos 2010; 38:1362-70.

Kusirisin W, Jaikang C, Chaiyasut C, Narongchai P. Effect of polyphenolic compounds from Solanum torvum on plasma lipid peroxidation, superoxide anion and cytochrome P450 2E1 in human liver microsomes. Med Chem 2009; 5:583-8.

Kusminski CM, Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Clin Pharmacol Ther 2009; 86:592-5.

Kuss BJ, O’Neill GM, Eyre H, Doggett NA, Callen DF, Davey RA. ARA, a novel ABC transporter, is located at 16p13. 1, is deleted in inv(16) leukemias, and is shown to be expressed in primitive hematopoietic precursors. Genomics 1998; 51:455-8.

Kusumi I, Masui T, Koyama T. Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:520-2.

Kusumoto M, Ueno K, Oda A et al. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. Clin Pharmacol Ther 2001; 69:104-7.

Kusztal M, Radwan-Oczko M, Kocielska-Kasprzak K, Boratyska M, Patrzaek D, Klinger M. Possible association of CTLA-4 gene polymorphism with cyclosporine-induced gingival overgrowth in kidney transplant recipients. Transplant Proc 2007; 39:2763-5.

Kuwabara T, Han KH, Hashimoto N et al. Tartary buckwheat sprout powder lowers plasma cholesterol level in rats. J Nutr Sci Vitaminol 2007; 53:501-7.

Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009; 26:715-37.

Kuypers DR, de Jonge H, Naesens M et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008; 30:673-83.

Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82:711-25.

Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18:861-8.

Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther 2010; 32:2012-23.

Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 2010; 32:394-404.

Kvernmo T, Houben J, Sylte I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem 2008; 8:1049-67.

Kwak JO, Lee SH, Lee GS et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 2010; 627:92-8.

Kwan P, Baum L, Wong V et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 2007; 11:112-7.

Kwan P, Li HM, Al-Jufairi E et al. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 2010; 39:192-7.

Kwan P, Poon WS, Ng HK et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 2008; 18:989-98.

Kwan P, Wong V, Ng PW et al. Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics 2009; 10:723-32.

Kwan P, Wong V, Ng PW et al. Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics 2011; 12:319-25.

Kwan TK, Ma ES, Chan YY et al. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure. Hong Kong Med J 2009; 15:365-73.

Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009; 23:2101-6.

Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol 2010; 6:55-68.

Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm 2010; 395:114-21.

Kweekel DM, Koopman M, Antonini NF et al. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 2008; 99:1316-21.

Kwok JB, Loy CT, Hamilton G et al. Glycogen synthase kinase-3beta and tau genes interact in Alzheimer’s disease. Ann Neurol 2008; 64:446-54.

Kwok JB, Teber ET, Loy C, Hallup M et al. Tau haplotypes regulate transcription and are associated with Parkinson’s disease. Tau haplotypes regulate transcription and are associated with Parkinson’s disease. Ann Neurol 2004; 55:329-34.

Kwon MJ, On YK, Ki CS et al. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype. Clin Chim Acta 2011; 412:2343-5.

Kwon OD, Khaleeq A, Chan W, Pavlik VN, Doody RS. Apolipoprotein E polymorphism and age at onset of Alzheimer’s disease in a quadriethnic sample. Dement Geriatr Cogn Disord 2010; 30:486-91.

Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011; 152:457-67.

Kyle-Cezar F, Echevarria-Lima J, Rumjanek VM. Independent regulation of ABCB1 and ABCC activities in thymocytes and bone marrow mononuclear cells during aging. Scand J Immunol 2007; 66:238-48.

Kyoung Pyo H, Lovati E, Pasinetti GM, Ksiezak-Reding H. Phosphorylation of tau at THR212 and SER214 in human neuronal and glial cultures: the role of AKT. Neuroscience 2004; 127:649-58.

Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68:592-7.

Kyrönlahti A, Vetter M, Euler R et al. GATA4 deficiency impairs ovarian function in adult mice. Biol Reprod 2011; 84:1033-44.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z